Musculoskeletal pain and ageing by Megale, Rodrigo Zunzarren
  
 
 
 
 
 
 
 
 
 
 
 
 
MUSCULOSKELETAL PAIN AND AGEING 
 
 
Rodrigo Zunzarren Megale, MBBS, MSc 
 
 
A thesis submitted in fulfilment of the requirements for the degree of 
 
Master of Philosophy (Medicine) 
 
School of Public Health, Sydney Medical School 
The University of Sydney 
2017 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Barbara   
  
 
 
 
 
  
 
 
 
    
 
 
                      
 
Concord Clinical School | The University of Sydney 
                     Date: 17 July 2017  
Associate Professor Paulo Ferreira 
Faculty of Health Sciences | The University of Sydney 
                      Date: 17 July 2017  
 iv 
Candidate’s Statement 
I, Rodrigo Zunzarren Megale, hereby declare that this submission is my own work and that it 
contains no material previously published or written by another person except where 
acknowledged in the text. Nor does it contain material which has been accepted for the award 
of another degree. 
 
I, Rodrigo Zunzarren Megale, understand that if I am awarded a higher degree for my thesis 
entitled “Musculoskeletal Pain and Ageing” being lodged herewith for examination, the thesis 
will be lodged in the University library and be available immediately for use. I agree that the 
University Librarian (or in the case of a department, the Head of the Department) may supply a 
photocopy or microform of the thesis to an individual for research or study or to a library. 
 
 
Rodrigo Zunzarren Megale 
Date: 17 July 2017 
  
 v 
Table of Contents 
Supervisors’ Statement ......................................................................................................... iii 
Candidate’s Statement  ......................................................................................................... iv 
Table of Contents .................................................................................................................. v 
Acknowledgements  ........................................................................................................... viii 
Abstract  ................................................................................................................................ x 
Chapter One: Introduction ................................................................................................................. 1 
   1.1 The burden of musculoskeletal pain in older adults ................................................................ 2 
   1.2 The contribution of coexisting conditions to the burden of musculoskeletal pain ..................... 3 
   1.3 Pain in musculoskeletal conditions ......................................................................................... 5 
1.3.1 Osteoarthritis ............................................................................................................................... 5 
1.3.2 Degenerative spine conditions .................................................................................................... 6 
1.3.3 Myofascial syndrome and fibromyalgia ....................................................................................... 7 
   1.4 Pain processing ...................................................................................................................... 8 
   1.5 The effect of age and age-related conditions on musculoskeletal pain ................................... 10 
1.5.1 Effect of age on osteoarthritis and degenerative spine conditions........................................... 10 
1.5.2 Effect of age-related inflammation on the joint ........................................................................ 11 
1.5.3 Effect of age on pain processing ................................................................................................ 11 
1.5.4 Effect of non-pain comorbidities on pain .................................................................................. 12 
1.5.5 Multimorbidity ........................................................................................................................... 14 
1.5.6 Effect of frailty in musculoskeletal pain ..................................................................................... 14 
1.6 The management of musculoskeletal pain in older adults ........................................................ 17 
1.6.1 Paracetamol ............................................................................................................................... 19 
 vi 
1.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) ...................................................................... 20 
1.6.3 Opioids ....................................................................................................................................... 21 
1.7 Aims of the thesis ................................................................................................................... 22 
1.8 References ............................................................................................................................. 24 
Chapter Two: Association between pain and the frailty phenotype in older men: longitudinal results 
from the CHAMP  ............................................................................................................................. 39 
   Abstract  ................................................................................................................................... 43 
   Introduction  ............................................................................................................................. 45 
   Methods ................................................................................................................................... 46 
   Results  ..................................................................................................................................... 51 
   Discussion ................................................................................................................................. 52 
   Conclusion  ................................................................................................................................ 55 
   Acknowledgments  .................................................................................................................... 56 
   References  ............................................................................................................................... 57 
   Tables ....................................................................................................................................... 61 
Chapter Three: Management of vertebral compression fracture in general practice: BEACH program . 66 
   Abstract  ................................................................................................................................... 68 
   Introduction  ............................................................................................................................. 69 
   Methods ................................................................................................................................... 70 
   Results  ..................................................................................................................................... 71 
   Discussion ................................................................................................................................. 73 
   Conclusion  ................................................................................................................................ 76 
   Acknowledgments  .................................................................................................................... 76 
   References  ............................................................................................................................... 77 
 vii 
   Letter to the Editor – correction request .................................................................................... 77 
Chapter Four: Efficacy and safety of oral and transdermal opioid analgesics for musculoskeletal pain in 
older adults: a systematic review of randomized, placebo-controlled trials  ....................................... 81 
   Abstract  ................................................................................................................................... 84 
   Introduction  ............................................................................................................................. 85 
   Methods ................................................................................................................................... 86 
   Results  ..................................................................................................................................... 90 
   Discussion ................................................................................................................................. 94 
   Acknowledgments  .................................................................................................................... 97 
   Tables and figures  ..................................................................................................................... 98 
   References  ............................................................................................................................. 111 
Chapter Five: Conclusion .................................................................................................... 119 
   5.1 Overview of principal findings   .......................................................................................... 120 
   5.2 Implications and directions for future research  .................................................................. 123 
5.2.1 Pain and frailty  ........................................................................................................................ 123 
5.2.1 Pain and frailty  ........................................................................................................................ 125 
   5.3 Concluding remarks ........................................................................................................... 127 
   5.3 References   ....................................................................................................................... 129 
Appendix A ........................................................................................................................ 134 
Appendix B   ...................................................................................................................... 137 
  
 viii 
Acknowledgments 
 
Firstly, I would like to thank my wife, Barbara, who has always been very supportive of me in my 
career and has always inspired me to pursue my dreams. 
I also would like to express my sincere gratitude to my main supervisor, Associate Professor 
Manuela Ferreira, for her guidance, her patience and her help, from my application to the 
submission of this thesis. I could not have done it without your help. 
Professor Fiona Blyth and Associate Professor Vasi Naganathan, I am indebted to you. You 
provided me with inspiration and advice. I hope we can still work together in the future.  
Associate Professor Paulo Ferreira, thank you for your warm support. Having you around helped 
me deal with the homesickness. I thank you as a co-supervisor and a friend. 
Professor David Hunter, thank you for having me in your department. You are the politest person 
and the most inspiring researcher I have ever met. I also thank all the people from the Institute 
of Bone and Joint Research. Special thanks to Luciano Mello, who have become more than a 
department mate. Luciano, you have a friend in me. 
Leticia, Ricardo, Daniel, Gustavo, Marina, Bruno, Tie and Patricia, having you around when I was 
living in Sydney made this life experience unique. I look forward to seeing you again.  
Rennell Potter, I have no words to express my gratitude to you. I miss you so much. I will forever 
remember our afternoon conversations. You taught me more than you could ever imagine.  
 ix 
My beloved family, Luiz, Carime, Eduardo, Alexandre and Joao Luiz, you have provided love and 
emotional support in tough moments.  
Finally, I have to thank my son Pedro. Your arrival made me realize what really, truly matters in 
life.       
 x 
Abstract 
 
Musculoskeletal pain is a complex phenomenon involving biomechanics, inflammation and 
central pain processing pathways. The ageing process and ageing-related conditions can affect 
the course of musculoskeletal pain; conversely, the presence of pain can affect the ageing 
process, contributing to increased risks of adverse health outcomes. Despite the importance of 
managing pain in older adults, questions remain in terms of the best approach as the use of 
analgesics in this population is associated with increased risks of adverse events. This thesis 
contributes to the current knowledge of how age-related conditions such as multimorbidity and 
frailty interact with musculoskeletal pain and its management. The specific aims are: a) to 
determine whether frailty status is a risk factor for development of chronic or intrusive 
musculoskeletal pain; b) to determine whether pain increases the risk of developing the frailty 
phenotype; c) to describe the current management of vertebral compression fractures, a 
common and painful musculoskeletal condition typically seen in older adults; and d) to review 
and appraise the literature on the efficacy and safety of opioid analgesics for older adults with 
musculoskeletal pain. 
To address the first and the second aims, longitudinal data from the Concord Health and Ageing 
in Men Project (CHAMP), a prospective population based cohort study, were used. A total of 1705 
men aged 70 years or older, living in an urban area of New South Wales, Australia, were included 
in the CHAMP baseline study. Data on the presence of chronic pain (daily pain for at least 3 
months), intrusive pain (pain causing moderate to severe interference with activities) and the 
criteria for the Cardiovascular Health Study frailty phenotype were collected in three waves, from 
 xi 
January 2005 to October 2013. After adjusting for potential confounders, no association between 
frailty and future chronic or intrusive pain was observed. However, non-frail (robust and pre-frail) 
men who reported chronic pain were 1.60 (95% confidence interval (CI): 1.02 to 2.51, p=0.039) 
times more likely to develop frailty at follow-up, compared to those with no pain. For those 
reporting intrusive pain, the odds of developing future frailty were 1.64 (95%CI: 0.97-2.78, 
p=0.063). In summary, the presence of chronic pain increased the risk of developing the physical 
frailty phenotype in community-dwelling older men. 
To address the third aim, data from the Bettering the Evaluation And Care of Health (BEACH) 
program collected between April 2005 and March 2015 were used. Each year, a random national 
sample of approximately 1,000 GPs each recorded information on 100 consecutive patient 
encounters. All encounters at which vertebral compression fracture was managed were selected. 
Vertebral compression fractures were managed in 211 (0.022%; 95% CI: 0.018–0.025) of the 
977,300 BEACH encounters recorded April 2005– March 2015. At encounters with patients aged 
50 years or over, prescription of opioids analgesics (47.1 per 100 vertebral fractures; 95% CI: 
38.4–55.7) was the most common management action. Prescriptions of paracetamol (8.2 per 100 
vertebral fractures; 95% CI: 4-12.4) or non-steroidal anti-inflammatory drugs (4.1 per 100 
vertebral fractures; 95% CI: 1.1-7.1) were less frequent. Non-pharmacological treatment was 
provided at a rate of 22.4 per 100 vertebral fractures (95% CI: 14.6-30.1). In summary, 
prescription of oral opioid analgesics remains the commonest general practice approach for 
vertebral compression fractures management, despite the lack of evidence to support this 
approach. 
 xii 
The fourth aim concerns the efficacy and safety of using opioid analgesics in older adults with 
musculoskeletal pain. A systematic review with meta-analysis was performed including 23 
randomized controlled trials with mean population age of 60 years or older that compared the 
efficacy and safety of opioid analgesics with placebo for musculoskeletal pain conditions. Opioid 
analgesics had a small effect on decreasing pain intensity (Standardised mean difference (SMD): 
-0.27; 95% CI: -0.33 to -0.20) and improving function (SMD: -0.27, 95%CI: -0.36 to -0.18), which 
was not associated with daily dose or treatment duration. The risk of adverse events was three 
times higher (OR: 2.94; 95% CI: 2.33 to 3.72) and treatment discontinuation four times higher 
(OR: 4.04; 95% CI: 3.10 to 5.25) in opioid treated patients. The systematic review concluded that, 
in older adults suffering from musculoskeletal pain, using opioid analgesics had only a small effect 
on pain and function at the cost of a higher risk of adverse events and treatment discontinuation. 
Therefore, for this specific population, the opioid-related risks may outweigh the benefits. 
From the results presented in the chapters of this thesis, important conclusions can be drawn: a) 
chronic musculoskeletal pain increases the risk of developing frailty in older adults and therefore, 
pain management should be part of a potential strategy to prevent frailty; b) despite being 
commonly prescribed for musculoskeletal pain in older adults, opioid analgesics alone are not 
likely to result in significant relief of chronic pain in these patients; c) instead of recommending 
opioid analgesics for persistent pain in older patients, guidelines should recommend 
comprehensive pain assessment, multimodal strategies and multidisciplinary approaches.  
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CHAPTER ONE 
Introduction  
  
 2 
Treating older patients suffering from musculoskeletal pain, particularly chronic musculoskeletal 
pain, is quite complex. Not only the ageing process and ageing-related health conditions affect 
the course and the management of musculoskeletal diseases but also the presence of pain can 
affect how well these patients age. This thesis reviews the mechanisms of pain underlying the 
most common musculoskeletal conditions affecting older adults; the influence of ageing and 
ageing-related health conditions on pain; and the current literature on pharmacological pain 
management in older adults. In addition, important gaps in the literature are identified. In order 
to bridge these gaps, this thesis has focused in addressing the following clinical questions: a) Are 
frail older adults at increased risk of developing chronic or intrusive pain? b) Does the presence 
of pain increase the risk of developing the frailty phenotype? c) How have clinicians been treating 
pain in patients with vertebral compression fractures (a condition typically seen in older adults)? 
d) What is the role of opioid analgesics in the management of older patients with musculoskeletal 
pain? 
 
1.1 The burden of musculoskeletal pain in older adults 
The prevalence of degenerative musculoskeletal conditions increases steadily with age, as does 
the prevalence of musculoskeletal pain. Around one in every two adults older than 65 years is 
affected by symptomatic arthritis (1), most commonly in the knees (2, 3) and hips (4); and one in 
every five reports back pain (5). Musculoskeletal pain is known to result in severe disability and 
impaired quality of life in older adults (6). Scudds and Robertson have conducted a cross-sectional 
study including 885 community-dwelling older Canadians and found that the presence of severe 
pain increased fourfold the odds of disability (7). This could be explained by the higher number 
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of associated comorbidities, reduced physiologic reserves, slower rate of tissue healing (8) and 
accelerated muscle loss after a period of rest (9) observed in people aged 60 or older. In another 
cross-sectional study, at least one third of community-living older women attributed their 
difficulties in basic and instrumental activities of daily living (ADL) to musculoskeletal pain; and 
one quarter of women who had difficulties walking 0.25 miles reported hip or knee osteoarthritis 
as the main cause for their mobility impairment (10). Musculoskeletal pain in older adults is not 
only highly prevalent and frequently disabling but also very costly, particularly considering the 
increasing role of surgical treatment in this condition (11, 12).  
 
Despite the burden associated to musculoskeletal pain in older adults, there is limited research 
guiding the best and most appropriate management for this condition. Older adults constitute a 
very heterogeneous group of individuals and probably the best management of musculoskeletal 
pain depends on factors other than the age itself. Particularly, the presence of comorbidities, 
pain-related functional impairment and the frailty status seem to be important variables to be 
considered managing musculoskeletal pain in older adults. 
 
1.2 The contribution of coexisting conditions to the burden of musculoskeletal pain  
As the population ages, the prevalence of multiple coexisting diseases has increased substantially 
(13). In Australia, 57.2% of people aged 65 years or more attending to primary care services have 
three or more diagnosed chronic conditions and 9.4% have seven or more diagnosed chronic 
conditions (14). The effects of accumulated comorbid load (i.e. multi-morbidity) in individuals 
with musculoskeletal pain, however, are not fully understood.  
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Individuals dealing with the management of multiple conditions are exposed to chronic stress 
and usually have more psychological, behavioural and social demands (15). While short-term 
fluctuations in stress-induced responses are needed to successfully deal with a particular 
stressor, excessive activation of stress, arousal and attentional circuits could increase nociception 
from periphery (16, 17) resulting in changes in pain modulation and processing.   
 
Frailty is also an important contributor to the burden of musculoskeletal pain. Several studies 
have shown the association between pain and frailty in different populations (18-24). Frailty-
related changes in the brain might impair descending inhibitory pain pathways increasing pain 
intensity in frail individuals. Moreover, hypothalamic-pituitary-adrenal (HPA) axis dysfunction, 
commonly associated with frailty (25), might contribute to chronic pain (26). Another explanation 
for such association is that persistent pain might lead to mobility impairment, depressive 
symptoms, lack of sleep, loss of appetite, and increase in the burden of medical comorbidities, a 
phenomenon called “pain homeostenosis”, that could precipitate or worsen frailty (22).  
 
Therefore, in order to understand the burden of musculoskeletal pain in older adults, frailty 
status as well as age, gender, presence of multi-morbidity and other health-related features must 
be considered. Those health-related aspects of the older patient, added to non-health-related 
factors such as socioeconomic status, cultural background, health beliefs and locus of control 
(27) bring greater complexity, to the clinical management of musculoskeletal pain in this 
population. 
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1.3 Pain in musculoskeletal conditions 
It is known that more than 50% of older adults are affected by symptomatic arthritis (1), most 
commonly in their knees, hips, hands and spine. Around 25% of people over 55 years have knee 
pain, mostly due to osteoarthritis (3). Also, 5% of people over 65 years have radiologic signs of 
hip osteoarthritis (4). In the spine, radiographic signs of disc or joint degeneration can be found 
in more than 90% of older adults and around 20% will report back pain (5). It is important to 
highlight that painful musculoskeletal conditions in older adults often occur together as 
comorbidities. In the following sections, the most common musculoskeletal conditions affecting 
older patients will be discussed. Particular attention will be paid to the mechanisms of pain 
underlying these conditions. 
  
1.3.1 Osteoarthritis 
The source of pain in osteoarthritis is not fully understood. Mechanical and inflammatory factors 
are not sufficient to explain the differences between pain intensity and the degree of joint 
damage in a lot of patients (28). In the past, osteoarthritic pain was believed to be mostly of 
nociceptive nature (i.e. caused by damage to body tissues). However, the observation that some 
patients with osteoarthritis can feel pain at sites distant from the inflamed joints and also report 
increased tenderness over supposedly normal tissues suggests changes in central modulation of 
pain might contribute to pain in osteoarthritis (29). Damage to articular cartilage has received 
substantial attention in the pathophysiology of osteoarthritis; however, its importance in the 
mechanism of pain is limited. Since cartilage tissue is both avascular and aneural, pain must be 
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arising from other structures such as joint capsules, ligaments, synovium or bones (30). 
Particularly, synovium inflammation (31) and bone marrow lesions (32) seem to be important 
sources of pain in osteoarthritis. 
 
1.3.2 Degenerative spine conditions 
Mechanical low back pain can originate from many structures of the spine, including 
intervertebral discs, facet joints, ligaments, paravertebral musculature and fascia, and spinal 
nerve roots (33). Lumbar disc degeneration is believed to be the most common cause of low back 
pain in older adults. Unfortunately, there is no clear boundary between the aging changes and 
pathological degeneration of the disc (34). Degenerative spine conditions are very common in 
older adults, but are often asymptomatic. For instance, disc herniation is found in around 40% of 
asymptomatic 80-years-old individuals, whilst signs of disc degeneration are found in almost all 
of them  (35).  
 
Another common source of low back pain in older people is osteoarthritis of the facet joints (36). 
Facet joints are synovial joints in the spine and subject to the same degenerative and 
inflammatory changes observed in other synovial joints (37). Particularly in older adults, two 
conditions contribute to higher prevalence of facet joint osteoarthritis: disc degeneration and 
paraspinal muscle weakness. Degenerative disc disease and facet joint osteoarthritis are 
frequently associated given that lesions which affect the disc tend to also have an effect on the 
facet joints (36). In some patients, the degenerative process in the spine can lead to hypertrophy 
of vertebral joint facets, bulging of the intervertebral disc and thickening of ligamentum flavum, 
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narrowing the spinal canal (38). This condition, called spinal stenosis, can result in symptoms of 
neurogenic claudication (39), low back pain and radiculopathy.  
 
Besides the above mentioned conditions, osteoporotic vertebral fractures should also be 
considered as a possible cause of low back pain in older adults (40, 41). These fractures are 
seldom seen in younger adults but are particularly common in older women (42, 43). They can 
cause significant acute pain at the time of their occurrence (44, 45) and can also cause persistent 
pain, compromising function and quality of life (46-51). Chapter Three of this thesis will focus on 
this condition. 
 
1.3.3 Myofascial syndrome and fibromyalgia  
The two most common conditions associated with muscular pain in older adults are myofascial 
pain syndromes and fibromyalgia. Despite their overlapping features, these are separate entities. 
In myofascial pain syndromes, the pain is often regional and occurs in physiologically abnormal 
muscles as the presence of taut bands are usually necessary for the development of trigger points 
(52). On the other hand, no structural or functional abnormalities are found in the muscle tissue 
of fibromyalgia patients, and pain is caused by dysfunctional pain processing mechanisms in the 
central nervous system (53). The augmentation of pain signals within the spinal cord through 
central sensitisation seems to be the most important factor in the development of fibromyalgia 
(54).  
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1.4 Pain processing 
In bones and joints, pain signals are carried by A-delta and C fibres (peripheral nociceptors). The 
thinly myelinated A-delta fibres are involved in the rapid detection and signalling of nociceptive 
stimuli such as pin pick and noxious mechanical stimuli, leading to an acute sensation of sharp 
pain. The unmyelinated C fibres, on other hand, respond to a broader range of painful stimuli, 
producing slow, burning, and long lasting pain (55).  
 
The peripheral nociceptor neuron enters the spinal cord through the dorsal horn, where it 
synapses with a second-order neuron. Depending on stimulation frequency and intensity, a 
postsynaptic output may be produced. Pain-related signals then ascends in contralateral 
spinothalamic tract to the thalamus (56). 
 
The thalamus receives pain inputs from spinothalamic tract and brainstem, acting as a relay 
centre for cortical afferent information. In the lateral thalamus, the second-order neuron 
synapses with the third-order neuron, which projects via the internal capsule and corona radiata 
to the primary somatosensory cortex (S1). This pathway is responsible for the sensory 
discriminative component of pain. The medial thalamus, on the other hand, projects diffusely to 
wide areas of the cortex making up the “medial pain system” that modulates the affective 
dimension of pain and control autonomic activity  (57). As a result, the involvement of the cortex 
in pain processing is not restricted to S1. Indeed, others cortical and subcortical brain regions 
were found to be commonly activated by nociceptive stimulation, such as the secondary 
somatosensory cortex (S2), anterior cingulate cortex, anterior insula, prefrontal cortex, posterior 
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parietal cortex and amygdala (58, 59). The amygdala, particularly, which is associated with 
biological responses to emotions, anxiety, and stress, is believed to be very important in central 
pain processing, integrating pain, fear and anxiety. 
 
As soon as the painful stimulus reaches the brain, the descending pain modulatory circuit, which 
includes the amygdala, thalamus, periaquedutal grey region, locus ceruleus, rostral ventromedial 
medulla and dorsal reticular nucleus, is activated. The activation of this descending circuit results 
in decreased pain perception in areas away from the stimuli. The presence of persistent 
musculoskeletal pain can decrease the efficacy of the descending pain control (60) and can 
contribute to the development of widespread pain in patients with musculoskeletal conditions.  
Higher cortical functions can also positively or negatively modulate nociceptive inputs and 
contribute to this endogenous pain regulatory system. Anxiety (61) and attention (62) seems to 
be particularly important.  
 
In summary, pain processing is highly complex and dynamic, and involves tissue damage, 
nociceptive inputs, cortical pain responses (activation of the descendent pain inhibitory 
pathways), attention, anxiety, cultural factors, past experiences and many other variables (63). 
That makes pain a feeling that varies in intensity according not only to the source of pain but also 
the individual who is suffering from pain.    
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1.5 The effect of age and age-related conditions on musculoskeletal pain 
1.5.1 Effect of age on osteoarthritis and degenerative spine conditions 
Like most of the age-related conditions, osteoarthritis results in part from loss in the efficiency 
of cells and tissues to maintain homeostasis, notably under stress. Chondrocyte senescence 
caused by oxidative stress, low grade inflammation, decreased levels or decreased growth factors 
responsiveness, decreased autophagy and increased matrix calcification are some mechanisms 
probably involved in the loss of joint homeostasis (64, 65). It is rare to find older adults without 
radiographic signs of osteoarthritis in at least one joint. Besides degenerative changes in 
meniscus and joint ligaments, increased joint laxity, increased bone turnover, subchondral bone 
marrow lesions and calcification of joint tissues (65, 66) sarcopenia and altered proprioception 
are also relevant factors involved in the higher susceptibility to osteoarthritis in older adults. 
 
In the spine, ageing-related degeneration begins in the discs, in which decreased vascularization 
affect the ability of disc cells to synthesize the extracellular matrix (34), causing the discs to lose 
fluids and proteoglycans (33). Macroscopically, the disc height decreases, the border between 
nucleus and annulus become less distinct and concentric fissuring and radial tears may appear. 
Disc degeneration, in turn, causes osteoarthritis of facet joints, which is characterized by joint 
hypertrophy, apophyseal malalignment, degenerative instabilities including spondylolisthesis, 
and osteophyte formation. The ageing-related spinal changes are also responsible for foraminal 
and central canal stenosis, frequently observed in older adults (36, 38).   
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1.5.2 Effect of age-related inflammation on the joint 
Several studies have shown higher levels of C-reactive protein (CRP), interleukin-6 (IL-6) and 
tumour necrosis factor alpha (TNF-α) in older people. This low-grade pro-inflammatory state 
produced by the ageing process seems to be critical in many ageing-related diseases such as 
Alzheimer’s disease, atherosclerosis and macular degeneration (67).  
 
Although osteoarthritis has been traditionally classified as a non-inflammatory arthritis, synovitis 
is present in a significant proportion of patients (68). In addition to local inflammation, age-
related systemic inflammation, also referred to as “inflamm-ageing”, have been associated with 
joint tissue destruction, pain and disability (69). This is particularly true in older adults with higher 
levels of CRP (70) or IL-6 (71). 
 
1.5.3 Effect of age on pain processing 
Although some studies have shown that older adults have relatively lower levels of pain 
complaints in several clinical conditions such as myocardial ischemia, intra-abdominal infections, 
cancer, and inflammatory diseases (72), it does not necessarily mean that there is an age-related 
decrease in pain sensitivity per se. Actually, the effect of age on pain perception cannot be simply 
summarized as increase or decrease in sensitivity to pain. Age-related changes in pain perception 
depend on the kind of noxious stimuli used, its duration and the region where it is applied. For 
instance, while older adults present increased pain thresholds for heat stimuli (72), they present 
decreased pain thresholds for mechanical stimuli  (73, 74), reflecting differences in the effect of 
ageing on superficial and deep tissue nociception. Moreover, even in situations in which the pain 
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threshold is increased, once it is reached, older adults tend to be less tolerant to pain and usually 
experience pain for longer periods after the tissue damage (75).  
 
Several mechanisms are involved in age-related changes in pain sensitivity. In the aged peripheral 
nervous system, A-delta fibre nociceptive function seems to be impaired while the C nociceptive 
fibres function remains intact (76), which means that older adults rely mostly on unmyelinated 
fibres carrying the painful stimuli to the second-order neuron. In the central nervous system, the 
altered cerebral processing of signals from pain stimuli and the reduced ability to down-regulate 
pain through descending inhibitory pain pathways (77) are the main differences observed in 
some older adults. However, these ageing-related changes vary considerably among individuals, 
reflecting genetics, the presence of comorbidities, mental health, lifestyle and socio-economic 
factors.  
 
1.5.4 Effect of non-pain comorbidities on pain 
Most individuals accumulate chronic non-painful conditions throughout their ageing process. 
There is vast evidence suggesting that these conditions are associated with changes in pain 
processing, inflammation or osteoarthritis progression.  Hypertension, for instance, can stimulate 
baroreceptors in aorta and carotid arteries, which send afferent signals to the brain areas 
involved in the descending pain inhibitory pathways (78). This would cause a “BP-related 
hypoalgesia” (79-81). However, in older adults experiencing chronic hypertension, the 
continuous input might lead to exhaustion or failure of the systems responsible for the “BP-
related hypoalgesia”, explaining the positive association between hypertension and chronic pain 
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(82). Likewise, there is an association between chronic obstructive pulmonary disease (COPD) 
and chronic pain. More patients with COPD have chronic pain and use pain medication than 
patients with other non-rheumatic chronic comorbidities (83). However, that mechanisms 
underlying these associations are not fully elucidated. As previously mentioned, there are also 
clinical conditions associated with inflammation, such as obesity and diabetes, which can 
contribute to the progression of osteoarthritis. In obese older adults, cytokines produced by 
adipose tissue act as a systemic mediator in osteoarthritis progression producing a low grade 
inflammation environment (84). Likewise, hyperglycaemia can cause joint tissue damage by 
increasing the local formation of advanced glycation end products (AGEs) and by inducing a low 
grade inflammation state (85).  
 
Besides physical comorbidities, mental conditions commonly present in older adults can also 
affect musculoskeletal pain. Depressed mood, for instance, has been associated with alterations 
in central pain processing (86), particularly dysfunctions in central pain inhibitory mechanisms 
(87). This is consistent with the finding that individuals with depressive symptoms have reduced 
effectiveness of pain interventions (88). On the other hand, older adults with chronic pain have 
more chances of subsequent depressed mood (89). It means that depression can adversely affect 
musculoskeletal pain and vice versa. 
 
Anxiety can also affect musculoskeletal pain. It is known that anxiety disorders in patients with 
chronic arthritic pain are two times more prevalent than anxiety disorders in the general 
population (90). Anxious patients usually have lowered physiological threshold for alarm 
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reactions facing a stressor (90), causing them to develop chronic autonomic nervous system 
arousal (91) and dysregulation of the endogenous opioid system (92). This might reduce the 
threshold for musculoskeletal pain.  
 
1.5.5 Multimorbidity 
The co-occurrence of multiple chronic conditions in the same patient is usual in older people (93, 
94) and health practitioners should keep this in mind managing musculoskeletal pain in this 
population. The presence of other conditions usually affects an index condition through a 
synergistic effect, i.e., when two or more conditions co-exist, the effect is greater than what 
would be expected from the adding the effects of the conditions alone (95). Moreover, there may 
be a reason for the co-occurrence of diseases. The presence of a given disease can be a risk factor 
for the other, different conditions can share the same risk factors, or a third condition can be a 
risk factor for two diseases (27). Besides assessing the effects of each clinical condition in pain, 
models addressing ageing and musculoskeletal pain should take into account the number of 
comorbidities since this variable seems to have a greater impact than each disease taken alone.           
 
1.5.6 Effect of frailty in musculoskeletal pain 
Frailty is a medical syndrome characterized by a state of vulnerability in which decreased 
physiologic reserves lead to reduced ability to maintain or regain homeostasis after a stressor 
(96). Assessing frailty, however, can be challenging since it is not possible to measure 
physiological reserves in clinical practice. In the last decades, several tools to identify and screen 
for frailty in older adults have been proposed (97) and, two instruments, the Frailty Index (FI) and 
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the Cardiovascular Health Study (CHS) frailty phenotype, have become widely used (98).  
 
Although both measures were designed to detect frailty, they are not interchangeable (98). In 
the FI, a count of accumulated multidimensional deficits is used to assess frailty (99) and so, the 
presence of comorbidities and disabilities plays an important role determining the degree of 
frailty. On the other hand, the CHS frailty phenotype has tried to distinguish frailty from 
comorbidity or disability (100), operationalizing a physical frailty phenotype, which could be 
considered a pre-disability condition. The development of the CHS frailty phenotype criteria was 
based on a conceptual framework of a frailty cycle, which was validated in the CHS study. 
According to the authors, the core clinical presentations of the frailty phenotype are: a) 
unintentional weight loss, b) weakness, c) poor endurance and energy, d) slowed waking speed 
and e) low physical activity (101) and the presence of three of these criteria defines frailty. Studies 
addressing the association between pain and frailty are mostly cross-sectional (18, 20, 23), 
preventing us from determining causal relationships, or used the FI to assess frailty (22, 24), 
which has the risk of potential confounders, as the FI combines items related to physical frailty, 
comorbidity and disability.  
 
In 2008, Blyth et al. published the first study exploring the relation between physical frailty and 
intrusive pain. A significant association was found, even adjusting for demographic 
characteristics, number of comorbidities, opioid use and specific conditions such as depressed 
mood and arthritis (18). Afterwards, higher rates of moderate to severe pain and intrusive pain 
were found in frail Mexican American (19). Chen et al. also found an association between pain 
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and frailty in the Survey of Health and Living Status of the Elderly in Taiwan. In this survey, the 
prevalence of pain in non-frail was less than half the prevalence in frail elders (40.7% vs 87.9%) 
(20). In 2012, Shega et al. found that the self-report of moderate or greater pain was 
independently associated with frailty in a cross-sectional analysis of the second wave of the 
Canadian Study of Health and Ageing (CSHA). The authors suggested that persistent pain might 
precipitate or accelerate the frailty development through a phenomenon which they called “pain 
homeostenosis” (21, 22). The association between pain and frailty was reinforced by the finding 
that pain assessed by the Pain Impact Questionnaire (PIQ6) was associated with the presence of 
frailty in a sample of Portuguese community dwelling elderly (23). Past evidence is, however, 
based on results of cross-sectional studies and does not allow for the ascertainment of cause-
effect relationships between pain and frailty.  
 
The first longitudinal analysis testing the hypothesis that chronic widespread pain is a risk factor 
for frailty development was published in 2015. In this study, however, the association between 
pain and frailty did not take in consideration the possibility of a bidirectional relationship. 
Moreover, the authors used the FI approach to assess frailty and so, it is not known if the same 
association would be found using the frailty phenotype to assess frailty. Chapter Two of this 
thesis addresses the gaps above, using longitudinal results of the CHAMP (Concord Health and 
Ageing in Male Project), one of the world’s largest and most comprehensive epidemiological 
studies of ageing in men. The aims of this chapter are: a) to assess the risk of developing the 
frailty phenotype in community-dwelling older men with chronic musculoskeletal pain and b)  
to assess how frailty status influences the risk of developing chronic pain in this same population. 
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1.6 The management of musculoskeletal pain in older adults 
Musculoskeletal pain in older adults has well established characteristics. Although little is known 
about the influence of age and ageing-related conditions on musculoskeletal pain, some 
conclusions can be drawn: i) musculoskeletal pain is highly prevalent and frequently disabling in 
older adults ii) information derived from studies in the general population cannot be 
extrapolated to older individuals, particularly to those who are frail or have multimorbidity. As a 
consequence, what constitutes optimal pain management in older adults is still unclear. Older 
adults are the highest users of analgesics, however pain remains under-treated in the greater 
part of this population (102). Achieving optimal pain control in older people can be very 
challenging as drug-related adverse events frequently prevents dose progressions or drug 
combinations. Moreover, the presence of comorbidities can contraindicate the use of some 
analgesic classes. 
 
The population of older adults suffering from musculoskeletal pain is heterogeneous in terms of 
physiological reserves and presence of comorbidities, resulting in a less predictable response to 
analgesics (103). It is unlikely that frail elders and those with multiple morbidities will respond to 
analgesic drugs or other interventions in the same way healthy older adults do and so, it is 
suboptimal to extrapolate results from studies conducted in otherwise healthy older adults to all 
the population of aged people. Unfortunately, frail older people have been under-represented in 
most clinical trials (104), including those designed to investigate musculoskeletal pain 
management strategies, and the evidence for any kind of recommendation in this population is 
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scarce (103). The lack of evidence based guidelines on management of musculoskeletal pain 
management in older adults leaves clinicians to their own experience dealing with this condition. 
This is particularly true for pain associated with vertebral compression fractures, a prevalent 
condition in which the medical literature has focused more on the osteoporosis treatment to 
prevent future fractures than on the pain management required. Most vertebral compression 
fractures are seen in older patients and they can cause both acute and chronic pain. Therefore, 
this condition was used as the basis to study the pain management in older adults. Chapter Three 
aims to describe current management of an important source of musculoskeletal pain in older 
adults – vertebral compression fractures. Data from the BEACH (Bettering Evaluation and Care of 
Health) program was use to describe how Australian general practitioners have been treating 
vertebral compression fractures in the last ten years. The BEACH program is a continuous, cross-
sectional national study that collects information of about 100,000 encounters with general 
practitioners annually, providing reliable data to describe general practice activity.  
 
Our results suggest that the most common approach to older adults with vertebral compression 
fracture-related pain is the prescription of analgesic drugs. Three classes of analgesics are 
particularly common: paracetamol, non-steroidal anti-inflammatories (NSAIDs) and analgesic 
opioids. 
 
1.6.1 Paracetamol 
Most of the guidelines endorse the use of paracetamol as the first line care for several 
musculoskeletal conditions (105-109).  Traditionally viewed as an effective analgesic with 
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excellent tolerability, recent data have changed this view questioning both the safety and efficacy 
of paracetamol (110-112). Recent systematic review found that while the risk of having abnormal 
liver function tests increases fourfold in patients taking paracetamol, the effect of this analgesic 
in patients with pain due to osteoarthritis is quite small (<4 points in a 1-100 points pain scale) 
and probably not clinically meaningful (113).  
 
Paracetamol is considered to be a weaker inhibitor of the synthesis of prostaglandins (PGs) and 
its spectrum of action resembles particularly the selective cyclcooxygenase-2 (COX-2) inhibitors, 
except for a weaker analgesic and anti-inflammatory effect and differences in sites of action (114, 
115). While paracetamol acts in preferentially in central nervous system, NSAIDs selective COX-2 
inhibitors act in peripheral sites. The effect of ageing in paracetamol pharmacokinetics is more 
significant in the drug clearance, which is significantly lower in older adults, especially in frail 
elders (103, 116, 117). Given the concerns related to dose-dependent hepatotoxicity and, in a 
lesser extent, gastrointestinal complications (118) and nephrotoxicity (119), the daily use of the 
maximum recommended dose (4g/day) in frail elders might be inappropriate, particularly 
considering that paracetamol is contained in many over-the-counter combination products 
frequently used by older people.  
 
The evidence on the effectiveness of paracetamol for the management of certain 
musculoskeletal diseases is still unclear. However, when compared to other pharmacological 
treatment options, paracetamol is more tolerable and has fewer adverse effects. It makes this 
drug relatively more suitable for use in frail elders.  
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1.6.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Although NSAIDs are considered more effective for the management of inflammatory pain 
compared to paracetamol, gastrointestinal (120), cardiovascular (121) and renal (122) adverse 
effects have raised concerns about the use of NSAIDs in older adults. According to the American 
Geriatric Society (AGS) 2009 Panel on the Pharmacological Management of Persistent Pain in 
Older Persons, “NSAIDs and cox-2 selective inhibitors may be considered rarely and with extreme 
caution, in highly selected individuals” (109). The Osteoarthritis Research Society International 
(OARSI) also recommends caution in the use of NSAIDs in patients with cardiovascular risk factors 
or increased gastrointestinal risks (108). Considering that most of the older patients will present 
cardiovascular risk factors (123-125) and older age is itself a risk factor for gastrointestinal 
bleeding (126) this concern can be extended to older adults. Unfortunately, since many pain 
conditions are ageing-related, the use of NSAIDs increases with age. Older adults using NSAIDs 
are at risk of peptic ulcer, acute kidney injury, increased blood pressure and cardiovascular risk, 
hepatic injury, allergic reactions, dizziness, confusion, falls and even delirium (127). Because 
upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in 1% of 
patients treated for 3-6 months, and individuals aged 75 years or over have even higher risk, the 
AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults strongly 
recommends avoiding chronic use of NSAIDs. However, the AGS Beers Criteria consider its use 
acceptable when no other alternatives are effective and the patient can take gastro-protective 
agents.  
 
 21 
Although all the recommendations above mentioned, the use of NSAIDs among older adults is 
still significant (128) and therefore, NSAIDs-related adverse events are the leading cause of 
hospital admissions due to drug reactions (129). As many NSAIDs are available as over-the-
counter (OTC) drugs and the pain relief is rapidly felt by patients, NSAIDs are very popular among 
older adults who frequently are not aware of potential risks.  
 
A recent meta-analysis of the effectiveness of NSAIDs compared to placebo for low back pain 
found this drug is slightly more effective than placebo, at a cost of increased risk of 
gastrointestinal adverse events (130). In patients with knee osteoarthritis, a meta-analysis of 
placebo-controlled trials addressing the efficacy of NSAIDs found similar results, i.e. NSAIDs are 
slightly more effective than placebo reducing pain (131). The modest benefits of NSAIDs in pain 
are probably outweighed by the risk of serious adverse events, particularly among older adults.  
 
1.6.3 Opioids 
The doubts regarding the efficacy of paracetamol in musculoskeletal conditions and the concerns 
about the long-term use of NSAIDs have placed opioid analgesics as one of the most popular 
choices for the management of acute and chronic musculoskeletal pain. Recent meta-analyses 
have shown some evidence for short-term efficacy of opioids to treat chronic low back pain (132) 
and knee or hip osteoarthritis (133), however, in low doses (median daily dose in morphine 
equivalency of 51 mg), the modest benefits observed were offset by increased risks of adverse 
effects (133). For older adults, even though clinical trials have shown evidence of short-term 
efficacy and less likelihood of abuse or misuse behaviours (134), the higher rates of adverse 
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events such as constipation, nausea, dizziness and somnolence seems to limit the use of opioids 
in this population. One in four opioid-treated patients enrolled in clinical trials involving older 
adults discontinued treatment because of adverse events (134). 
 
In the United States, a population-based survey found that approximately 2 per cent of the 
respondents reported opioid use for at least one month. Arthritis and back pain were the most 
prevalent chronic conditions among opioid users (135). Although opioids have been commonly 
used for chronic musculoskeletal conditions, their safety and efficacy in older adults with 
musculoskeletal pain is still unclear. Chapter four presents a systematic review with meta-
analysis of randomised controlled trials with mean population age of 60 years or over, comparing 
opioid analgesics with placebo for musculoskeletal conditions on pain, function and quality of 
life, as well as the risks of opioids-related adverse events. 
 
1.7 Aims of the thesis 
The aims of this thesis were to: 
i) Investigate whether musculoskeletal pain is an independent risk factor for 
development of the frailty phenotype in older men (Chapter Two); 
ii) Investigate whether the frailty status is an independent risk factor for development 
of chronic or intrusive musculoskeletal pain (Chapter Two); 
iii) Describe the current management of vertebral compression fractures, a painful and 
disabling musculoskeletal condition commonly seen in older adults (Chapter Three); 
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iv) Systematically review and appraise the literature on the efficacy and safety of opioid 
analgesics for older adults with musculoskeletal pain (Chapter Four).  
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Abstract 
Objectives:  To determine whether pain increases the risk of developing the frailty phenotype 
and whether frailty increases the risk of developing chronic or intrusive pain, using longitudinal 
data. 
Design/Setting: Longitudinal data from the Concord Health and Ageing in Men Project (CHAMP), 
a prospective population based cohort study. 
Participants: A total of 1705 men aged 70 years or older, living in an urban area of New South 
Wales, Australia.  
Measurements: Data on the presence of chronic pain (daily pain for at least 3 months), intrusive 
pain (pain causing moderate to severe interference with activities) and the criteria for the CHS 
frailty phenotype were collected in three waves, from January, 2005 to October, 2013. Data on 
age, living arrangements, education, smoking status, alcohol consumption, body mass index, 
comorbidities, cognitive function, depressive symptoms and history of vertebral or hip fracture 
were also collected and included as covariates in the analyses.  
Results: 1,705 participants were included at baseline, of whom 1,332 provided data at the 2-year 
follow-up and 940 at the 5-year follow-up. Non-frail (robust and pre-frail) men who reported 
chronic pain were 1.60 (95% confidence interval (CI): 1.02 to 2.51, p=0.039) times more likely to 
develop frailty at follow-up, compared to those with no pain. Intrusive pain did not significantly 
increase the risk of future frailty. Likewise, the frailty status was not associated with future 
chronic or intrusive pain in the adjusted analysis. 
Conclusions:  The presence of chronic pain increases the risk of developing the physical frailty 
phenotype in community-dwelling older men. 
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Introduction 
Pain is very common among older adults (1-5). A wealth of evidence has established the 
association between pain and disability in the older population (6-10) and, more recently, 
between pain and frailty (11-17). Although positive association between pain and frailty has been 
showed in past research, a causal association has not been established yet. All but one of the 
previous studies addressing the association between pain and frailty are cross-sectional studies. 
The only longitudinal study (17) to look at this association found chronic widespread pain to be 
associated with worsening frailty as assessed using a Frailty Index (FI).  
 
Another common approach to assessing frailty is the use of the Cardiovascular Health Study (CHS) 
frailty phenotype criteria. The frailty phenotype distinguishes frailty from comorbidity and 
disability, defining a pre-disability syndrome based on specific clinical signs and symptoms (18). 
Therefore, CHS frailty criteria identify a group of frail older people sharing a common 
pathophysiological chain (19), which provides a framework for identifying etiologic factors and 
interventions to prevent further functional decline. While pain seems to be a risk factor for frailty 
as measured by deficit accumulation (17), whether it is also risk factor for physical frailty assessed 
using the CHS frailty criteria is still unknown. Moreover, it is possible pain and frailty hold a 
bidirectional risk relationship.  
 
We aimed to explore the association between pain and frailty using longitudinal data collected 
over 5 years. The objectives of this study were: 
1. To establish whether chronic pain or intrusive pain at baseline would increase the risk 
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of future frailty defined using the CHS criteria in older Australian men; 
2. To establish whether frailty status at baseline would predict the occurrence of future 
chronic or intrusive pain in older Australian men. 
 
Methods 
Study design and sample population 
The Concord Health and Ageing in Men Project (CHAMP) is a population-based cohort study of 
men aged 70 years or over, living in a defined geographical region near Concord Hospital in 
Sydney (20). The sampling frame used for the study was the New South Wales Electoral Roll. 
Eligible men in the study area were sent a letter describing the study and, if they had a listed 
telephone number, were contacted about one week later. Men without listed telephone 
numbers who did not respond to the first letter were sent a second invitation letter. Recruitment 
occurred sequentially across the geographic study area, with invitation letters being sent out 
each week during the recruitment period. The only exclusion criterion was living in a residential 
aged care facility. 
 
Baseline data were collected between January 28, 2005 and June 4, 2007. Invitation letters were 
sent to 3,627 men and contact was made with 3,005 men. One hundred and ninety of the 
contacted men were not eligible for the study because they had moved out of the study area, 
had moved into a nursing home or had died. Of the 2,815 eligible men with whom contact was 
made, 1,511 participated in the study (54%). An additional 194 eligible older men who lived in 
the study area heard about the study from friends or the media and asked to be in the study 
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before receiving an invitation letter. Two-year follow-up assessments were conducted between 
January 2007 and October 2009, and the 5-year follow-up was conducted between January 2012 
and October 2013. 
 
Pain assessment 
Chronic pain  
The presence of chronic pain was assessed through the question: “In the last 6 months, have you 
experienced pain in any part of your body which has lasted for 3 months or more, that is pain 
experienced every day for at least 3 months?”; this question has been widely used in population 
studies (4). Data were collected at baseline and at 2 and 5-year follow-ups.  
 
Intrusive pain  
The following question from the SF-12 questionnaire (21)  was used to assess the impact of pain 
on an individual’s life: “During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)?” Men who reported that their 
pain interfered “moderately”, “quite a bit” or “extremely” on normal work were classified as 
individuals with intrusive pain. 
 
Frailty assessment 
Frailty was assessed using the CHS frailty phenotype definition: weight loss/shrinking, weakness, 
exhaustion, slowness and low activity. The assessment of weakness and slowness used the 
standard CHS definition and cut-offs, but adapted criteria were used for weight loss/shrinking, 
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exhaustion, and low activity. The following definitions were used: a) weight loss/shrinking: 
defined as current weight 15% or more less than self-reported heaviest weight; b) weakness: 
defined as being in the lowest CHS study quintile for grip strength, adjusted for BMI; c) 
exhaustion: defined according to responses to the following question from the SF12: ‘‘How much 
of the time during the past 4 weeks did you have a lot of energy?”; d) slowness: defined as being 
in the lowest CHS study quintile for walking speed, adjusted for height; e) low physical activity: 
defined as being in the lowest quintile on the Physical Activity Scale for the Elderly (PASE) (cut-
off score <73). Individuals who met 3 or more criteria were classified as frail. Those meeting less 
than 3 criteria were classified as pre-frail (1 or 2 criteria) or robust (0 criteria). The presence of 
frailty and the frailty score were assessed at baseline and at 2-year and 5-year follow-ups.  
 
Socio-demographic and life-style factors 
Age, living arrangements (living alone vs. living with others) and level of education (no post-
school qualification vs. post-school qualification) were used to assess socio-demographic status 
of included participants. Participants were classified as having a post-school qualification if they 
answered “yes” to the following question: ‘‘Since leaving school have you obtained a trade 
qualification, certificate, diploma or any other qualifications?”  
 
Smoking status was classified as “never smoked” (those who smoked less than 100 cigarettes in 
their entire life), “ex-smokers” or “current smokers”. Alcohol abuse was assessed through the 
CAGE questionnaire (22), with two or more positive answers in the questionnaire used to 
determine “alcohol abuse”. Height and weight were measured, and body mass index (BMI) was 
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calculated as kilograms per square metre.  
 
Comorbidities 
The comorbidity count was calculated for each participant by summing the presence of 18 self-
reported, doctor-diagnosed conditions: diabetes; thyroid disease; osteoporosis; Paget’s disease; 
stroke, blood clot in the brain or bleeding in the brain; Parkinson’s disease; kidney stones; 
epilepsy or fits; hypertension or high blood pressure; heart attack, coronary or myocardial 
infarction; angina; congestive heart failure or enlarged heart; intermittent claudication or pain in 
the legs from a blockage of the arteries; chronic obstructive lung disease, chronic bronchitis, 
asthma, emphysema or COPD; liver disease; chronic kidney disease or kidney failure; arthritis or 
gout; and cancer (excluding non-melanoma skin cancer).  
 
Cognitive function and depressive symptoms 
The mini-mental state exam (MMSE) (23) score was used as a continuous measure to assess 
cognitive function. Depressive symptoms were evaluated with the Geriatric Depression Scale 
(GDS) 15-item version (24). A total of five or more depressive symptoms were considered as 
indicating a possible depressed mood.  
 
Statistical analysis 
The statistical analysis was carried out using STATA v13 (Stata Corp, College Station, TX). 
Descriptive characteristics were expressed as means and standard deviation (SD) for continuous 
variables and absolute number and percentage for categorical variables. The statistical 
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significance threshold was set at 0.05. 
 
Generalised estimating equations (GEE) were used to explore the association between pain and 
frailty. GEE takes into account the time-varying nature of included variables allowing for the 
inclusion of all three waves of data collection in the analyses. The analyses were performed using 
a time lag model in which predictors were always assessed in the previous wave. For the GEE 
models, exchangeable working correlation structure and robust standard errors were used. 
Unadjusted, age-adjusted and multivariate analyses were carried out. Covariates selected for the 
multivariate analysis were those significantly associated with the outcome of interest (p<0.1) 
when included in the model. The results are expressed as odds ratios (OR) and 95% confidence 
intervals (95%CI).  
 
Risk of developing frailty in participants with chronic pain or intrusive pain 
To ascertain evidence of the role of chronic pain or intrusive pain in frailty development, 
individuals who were classified as frail at baseline were excluded from this analysis. The GEE 
model included data from baseline, 2- and 5-year follow-ups. Participants without chronic pain 
and participants without intrusive pain were considered the reference group. 
 
Risk of developing chronic or intrusive pain in frail participants 
To ascertain the role of frailty status as a risk factor for pain, men who reported chronic pain or 
intrusive pain at baseline (according to the outcome of interest) were excluded from the analysis. 
The GEE model included data from baseline, 2 and 5-year follow-up.  Robust participants were 
 51 
considered the reference group. 
 
Ethics approval and informed consent 
All participants gave written informed consent. The study was approved by the Sydney Local 
Health District Human Research Ethics Committee, Concord Repatriation General Hospital, 
Sydney, Australia. 
 
Results 
1,705 patients were included in the baseline assessments. At the 2-year follow-up, frailty status 
was assessed in 1,332 participants and at the 5-year follow-up in 940 participants. Death was the 
main reason for nonparticipation at 2 years and at 5 years. The other main reason for failure to 
attend the follow-up clinic visits was illness.   
 
The mean (SD) age of the study population at baseline was 76.9 (5.5) years. Chronic pain was 
reported by 29.5% (n=501) of the participants and intrusive pain by 23.4% (n=392). Also at 
baseline, 50% (n=833) of the participants were classified as robust, 40.7% (n=679) as pre-frail and 
9.4% (n=158) as frail. Other baseline characteristics of the participants are summarized in Table 
1, as reported by the CHAMP researchers previously. 
 
Risk of developing frailty in participants with chronic pain and intrusive pain 
In GEE analyses presence of chronic pain in the previous wave was independently associated with 
increased odds of future frailty (OR 1.60, 95%CI 1.02-2.51, p=0.039) (Table 2).   
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Likewise, the GEE analyses suggested that the odds of developing frailty were higher in 
participants who reported intrusive pain (see Table 2). However, the association did not quite 
reach statistical significance in the fully adjusted model (OR 1.64, 95%CI 0.97-2.78, p=0.063).  
 
Risk of developing chronic pain or intrusive pain in pre-frail and frail participants 
Compared to robust individuals, pre-frail or frail individuals were not at a higher risk of reporting 
future chronic pain (OR 1.07, 95%CI 0.80-1.44; p=0.649 for pre-frail and OR 0.82, 95%CI 0.38-
1.79; p=0.618 for frail men) or intrusive pain (OR 0.91, 95%CI 0.67-1.23; p=0.551 for pre-frail and 
OR 1.38, 95%CI 0.70-2.74; p=0.356 for frail men) at follow-up, after adjusting for covariates (Table 
3).  
 
Discussion   
This study has shown that chronic pain in older men is a risk factor for developing frailty, as 
assessed using the CHS frailty criteria. However, frailty status is not associated with increased risk 
of developing chronic or intrusive pain. 
 
This is not the first study to demonstrate that chronic pain is associated with increased risk of 
frailty. Similar results were found in the European Male Ageing Study (EMAS), a cohort study with 
a younger population (mean age population of 59 years). However, both the chronic pain 
assessment and the frailty measure in the EMAS study were different from ours. The EMAS study  
assessed chronic widespread pain using the American Rheumatology Association (ARA) criteria 
for fibromyalgia (25) whereas we used the International Association for Study of Pain (IASP) 
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definition for chronic pain (“pain which has persisted beyond normal tissue healing”, usually 
taken as 3 months duration (26)) and intrusive pain (pain-related interference with activities 
(11)). In addition, the EMAS study assessed frailty using the FI whereas we used the CHS frailty 
phenotype criteria. Despite all these differences, EMAS and CHAMP found similar results 
regarding the association between chronic pain and frailty. 
 
The association between pain and physical frailty could be explained in several ways. The 
presence of pain might be acting as persistent stressor, demanding continuous activation of 
stress-related systems, which would consume physiological reserves and increase the risk of 
frailty (14, 15). Alternatively, systemic inflammation and the hypothalamic-pituitary-adrenal axis 
dysfunction, often found in patients with chronic pain (27, 28), could contribute to frailty 
development (29, 30). Regardless of the mechanisms underlying pain and frailty association, it 
has been suggested that persistent pain should be included as a sixth CHS frailty criterion because 
it usually occurs in association with other frailty criteria, increasing the risk of adverse outcomes 
(31).    
 
As frailty-related changes in the brain might cause impairments in descendent inhibitory pain 
modulation (14), it was expected that frailty would be a risk factor for pain. However, our study 
has shown that frailty status is not independently associated with increased risk of developing 
chronic or intrusive pain.  
 
In 2008, Blyth et al. published one of the first studies exploring the relation between frailty and 
 54 
pain using baseline data from this same cohort study  (11). The authors concluded that frailty was 
associated with intrusive pain at CHAMP’s baseline. Our longitudinal results, however, are not so 
clear regarding the association between intrusive pain and frailty development. Although the 
odds ratio for the association between intrusive pain and frailty is quite similar to the odds ratio 
for chronic pain and frailty association, the significant threshold was not met.  
 
The findings reported in this study have important clinical implications. If chronic pain increases 
the risk of frailty, then better pain management could reduce the frailty trajectory among older 
adults. However, randomised clinical trials are still needed to test whether and which pain 
interventions have any effect on frailty progression.      
 
Our study has a number of strength: a) data were collected prospectively in this large cohort of  
older men (mean age 77 years) which is significantly older that the previous study (17); b) 
standardised criteria for frailty were used with a standardised approach to definitions for all 
clinical variables; c) the longitudinal nature of this study is a major strength, with measurement 
of variables up to 5 years. Nevertheless, there are limitations that must be pointed out. Our 
results cannot be extrapolated to women, since men and women have different behaviours 
regarding pain (32) and frailty (33). Other important limitations are not including disease severity 
when examining comorbidities and the exclusion of information on pain medication from the 
analyses, given pain medication might mediate the association between pain and frailty (34).  
 
This study represents a step forward understanding the influence of chronic pain, a common 
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problem in aged populations, on frailty dynamics. However, many questions remain unanswered, 
for example, the biological mechanisms responsible for this association, the influence of pain 
characteristics (such as origin and intensity) on frailty progression and the impact of pain 
management on vulnerable populations.   
 
Conclusion 
We have established that the presence of chronic pain increases the risk of developing physical 
frailty phenotype in community-dwelling older men, even after adjusting for potential 
confounders. Conversely, we found that frailty is not an independent risk factor for chronic or 
intrusive pain. Future studies should focus on the efficacy of different pain management 
strategies in reducing the risk of frailty.  
 
Key Points 
• Chronic pain is an independent risk factor for developing the CHS frailty phenotype among 
older men 
• The frailty status does not independently increase the risk of developing chronic or 
intrusive pain among older men 
• Future studies should focus on the role of pain management as a potential strategy to 
prevent frailty in older people 
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Tables 
Table 1. Baseline characteristics of population (n=1705). 
 n (% or SD) 
Demographic factors  
Age, mean (SD) 76.9 (5.5) 
Living alone, n (%) 318 (18.8) 
Post-school qualification, n (%) 915 (54.5) 
Alcohol abuse (CAGE>=2), n (%) 76 (4.5) 
Cigarette-smoking status   
Never smoked, n (%) 630 (37.3) 
Ex-smoker, n (%) 956 (56.7) 
Current smoker, n (%) 101 (6.0) 
BMI, mean (SD) 27.8 (4.0) 
Mini-Mental, mean (SD) 27.1 (3.0) 
Depressive mood (GDS>=5) 246 (14.6) 
Hip or vertebral fracture, n (%) 50 (2.9) 
Comorbidity count, mean (SD) 1.4 (1.3) 
Chronic pain, n (%) 501 (29.5) 
Intrusive pain, n (%) 392 (23.4) 
Frailty status  
Robust, n (%) 833 (49.9) 
Pre-frail, n (%) 679 (40.7) 
Frail, n (%) 158 (9.4) 
 
Missing: living alone = 14, post-school qualification = 25, alcohol abuse = 14, smoking status = 
18, BMI = 28, MMSE = 186, depression = 24, comorbidity count = 16, chronic pain = 8, intrusive 
pain = 30, frailty status = 35 
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Table 2. Unadjusted, age adjusted and multivariate GEE analyses with a time lag assessing chronic 
or intrusive pain as a risk factor for frailty development (n=1,512) 
 Frailty  
 OR (95% CI) p 
Model 1. Chronic pain vs. Frailty   
Unadjusted model 1.71 (1.22-2.41) 0.002 
Age-adjusted model 1.77 (1.24-2.53) 0.002 
Age (years) 1.19 (1.15-1.23) <0.001 
Multivariate model1 1.60 (1.02-2.51) 0. 039 
Age (years) 1.17 (1.12-1.22) <0.001 
Living alone 0.92 (0.52-1.64) 0.789 
Post-school qualification  0.86 (0.54-1.37) 0.522 
BMI (kg/m2) 0.91 (0.87-0.96) <0.001 
Count of comorbidities (0-18) 1.40 (1.24-1.60) <0.001 
MMSE (0-30) 0.88 (0.83-0.94) <0.001 
Depression 4.20 (2.57-6.86) <0.001 
Model 2. Intrusive pain vs. Frailty   
Unadjusted model 2.32 (1.59-3.38) <0.001 
Age-adjusted model 2.45 (1.65-3.63) <0.001 
Age (years) 1.19 (1.15-1.23) <0.001 
Multivariate model2 1.64 (0.97-2.78) 0. 063 
Age (years) 1.17 (1.12-1.23) <0.001 
Living alone 0.96 (0.54-1.69) 0.879 
Post-school qualification  0.85 (0.53-1.34) 0.474 
BMI (kg/m2) 0.91 (0.87-0.96) <0.001 
Count of comorbidities (0-18) 1.38 (1.21-1.57) <0.001 
MMSE (0-30) 0.87 (0.82-0.93) <0.001 
Depression 3.99 (2.43-6.53) <0.001 
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1 Smoking status, alcohol abuse and history of hip/ vertebral fracture were not included 
because these variables were not significantly associated (p<0.1) with frailty when included in 
the GEE model. 
2 Smoking status, alcohol abuse and history of hip/ vertebral fracture were not included 
because these variables were not significantly associated (p<0.1) with frailty when included in 
the GEE model. 
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Table 3. Unadjusted, age adjusted and multivariate1 GEE analyses with a time lag assessing 
frailty status in the previous wave as a risk factor for development of chronic pain or intrusive 
pain.  
 Chronic pain (n=1,196) Intrusive pain (n=1,283) 
 OR (95% CI) p OR (95% CI) p 
Unadjusted model     
Pre-frail 1.15 (0.89-1.49) 0.286 1.21 (0.91-1.60) 0.173 
Frail 1.26 (0.70-2.27) 0.440 3.13 (1.85-5.27) <0.001 
Age-adjusted model     
Pre-frail 1.07 (0.82-1.40) 0.603 1.11 (0.83-1.48) 0.457 
Frail 1.12 (0.62-2.04) 0.706 2.61 (1.49-4.56) 0.001 
Age (years) 1.03 (1.00-1.05) 0.030 1.03 (1.00-1.05) 0.030 
Multivariate model1     
Pre-frail 1.07 (0.80-1.44) 0.649 0.91 (0.67-1.23) 0.551 
Frail 0.82 (0.38-1.79) 0.618 1.38 (0.70-2.74) 0.356 
Age (years) 1.03 (1.00-1.06) 0.021 1.04 (1.01-1.08) 0.012 
Post-school qualification 0.74 (0.55-0.99) 0.042 0.83 (0.62-1.11) 0.209 
Smoking status2  1.53 (1.17-2.00) 0.002 1.04 (0.79-1.36) 0.771 
BMI (kg/m2) 1.00 (0.97-1.04) 0.959 1.05 (1.01-1.09) 0.009 
Count of comorbidities (0-18) 1.10 (1.01-1.20) 0.024 1.32 (1.21-1.45) <0.001 
MMSE score (0-30)3 1.06 (1.00-1.12) 0.060 N/A N/A 
Depression 1.63 (1.07-2.50) <0.001 2.49 (1.66-3.73) <0.001 
1 Living alone, alcohol abuse, and history of hip/vertebral fracture were not included because 
these variables were not significantly associated (p<0.1) with frailty when included in the GEE 
model. 
2 Smoking status: never smoked, ex-smokers and current smokers. 
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3 MMSE score was not significantly associated (p<0.1) with intrusive pain when included in the 
GEE model. 
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CHAPTER THREE 
Management of vertebral compression fracture in general practice:  
BEACH program 
 
 
 
 
 
 
 
 
 
Chapter Three has been published as: 
Megale RZ, Pollack A, Britt H, Latimer J, Naganathan V, McLachlan AJ, Ferreira ML. (2017) 
Management of vertebral compression fracture in general practice: BEACH program. PLoS ONE 
12(5): e0176351. https://doi.org/10.1371/journal.pone.0176351. This chapter has been 
formatted according to the guidelines from the PLoS ONE. Please note the amendment at the 
end of this Chapter (letter to the Editor – correction request) 
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Letter to the Editor – correction request 
 
Dear Professor Michael G. Fehlings, 
 
The purpose of this letter is to call attention to a typographical error in a recent PLOS ONE 
publication (Megale RZ, Pollack A, Britt H, Latimer J, Naganathan V, McLachlan AJ, et al. (2017) 
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Abstract 
Objectives: This systematic review with meta-analysis was performed to evaluate the efficacy 
and safety of using opioid analgesics in older adults with musculoskeletal pain. 
Methods: We searched Cochrane Library, MEDLINE, EMBASE, Web of Science, AMED, CINAHL 
and LILACS for randomized controlled trial with mean population age of 60 years or older, 
comparing the efficacy and safety of opioid analgesics with placebo for musculoskeletal pain 
conditions. Reviewers extracted data, assessed risk of bias and evaluated the quality of evidence 
using the GRADE approach. Random-effects models were used to calculate standardized mean 
differences (when different scales were used across trials), mean differences and odds ratios with 
respective 95% CIs. Meta-regressions were carried out to assess the influence of opioid analgesics 
daily dose and treatment duration on our main outcomes. 
Results: We included 23 randomised placebo-controlled trials in the meta-analysis. Opioid 
analgesics had a small effect on decreasing pain intensity (Standardised mean difference (SMD): 
-0.27; 95% CI: -0.33 to -0.20) and improving function (SMD: -0.27, 95%CI: -0.36 to -0.18), which 
was not associated with daily dose or treatment duration. The risk of adverse events was three 
times higher (OR: 2.94; 95% CI: 2.33 to 3.72) and treatment discontinuation four times higher 
(OR: 4.04; 95% CI: 3.10 to 5.25) in opioid treated patients.  
Conclusions: In older adults suffering from musculoskeletal pain, using opioid analgesics had only 
a small effect on pain and function at the cost of a higher risk of adverse events and treatment 
discontinuation. For this specific population, the opioid-related risks may outweigh the benefits.  
Systematic review registration: PROSPERO registration number CRD42016037154  
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Introduction 
Although the use of opioid analgesics to treat acute pain or cancer related chronic pain is widely 
accepted, the benefits of using them to treat chronic musculoskeletal pain are still unclear. 
However, the use of opioids for chronic non-cancer pain has been endorsed by different clinical 
practice guidelines (1-3) based on the belief that these medicines can relieve pain and improve 
mood and function in selected patients (4). As a result, the rate of regular use of opioid analgesics 
has continued to increase in recent decades (5-8), raising concerns about the safety of these 
medicines and the risk of overuse and opioid-related adverse events (9, 10). This is particularly 
true for older patients, commonly affected by musculoskeletal pain conditions (11-13).  Despite 
the increasing popularity of these medicines, there is currently a lack of evidence regarding the 
efficacy and safety of opioid analgesics in older populations suffering from musculoskeletal pain.  
 
Previous systematic reviews addressing the use of opioid analgesics for patients with 
musculoskeletal pain (14-17) have not provided age-relevant recommendations on the efficacy 
and safety of these medicines for the older patient.  To our knowledge, only one systematic 
review, published in 2010, addressed the efficacy of opioid analgesics compared to placebo for 
older adults (18). The authors concluded that, in older adults, short-term use of opioid analgesics 
was associated with modest but favourable effects on chronic musculoskeletal pain. Since then 
seven new randomized trials including a large proportion of people aged over 60 years have been 
published in the field. How effective and safe opioid analgesics are in older people with 
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musculoskeletal pain is an important clinical question. A systematic, contemporary and 
comprehensive review of the literature may shed more light on this.  
 
The aims of this systematic review were: a) to investigate the efficacy of opioid analgesics 
compared to placebo, for the outcomes of pain, function and quality of life, in older adults with 
musculoskeletal pain; b) to investigate the safety of opioid analgesics in older patients looking at 
the outcomes of adverse events and treatment withdrawal reported in clinical trials.  
 
Methods 
Data sources and searches 
This systematic review was conducted following the PRISMA statement (19). A systematic 
electronic search was performed of the following databases: Cochrane Library, MEDLINE, 
EMBASE, Web of Science, AMED, CINAHL and LILACS. A combination of relevant keywords around 
randomised placebo-controlled clinical trials, opioid analgesics and musculoskeletal pain were 
used to construct the search strategy (see supplementary material).  
 
The first screening of potential relevant records was conducted by one author based on titles and 
abstract (R.Z.M.), and two authors (R.Z.M. and L.A.D.) independently performed the final 
selection of included trials based on full text evaluation. Consensus between the two reviewers 
was used to resolve any disagreement. 
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Study selection 
Only randomized controlled trials comparing the efficacy of opioid analgesics versus placebo for 
acute or chronic musculoskeletal pain were included in this review. Eligible trials needed to have 
a mean study population age of 60 years or older. When the mean was not available, a median 
age of 60 years or older was considered. Trials were included if they reported at least one of the 
following outcome measures: pain, disability, quality of life, treatment discontinuation due to 
lack of efficacy or adverse events or rate of adverse events. Studies including population with a 
range of pain conditions were included only if separated data were reported for musculoskeletal 
pain. 
 
Data extraction  
Using a standardized data extraction form, study characteristics (details of participants, 
interventions, and outcomes) were extracted from the included trials. Relevant data for outcome 
assessment were extracted by two independent authors (R.Z.M., L.A.D.). Any disagreement was 
resolved by consensus or with a third author (M.L.F.) as necessary. For pain intensity, disability 
and quality of life measures, change scores, final scores, standard deviations, and sample sizes 
were extracted. When more than one pain scale was reported, we extracted data from the scale 
reporting more severe pain at baseline. Missing standard deviations were estimated from 
standard errors, confidence intervals or p-values, using the methods described in the Cochrane 
Handbook (20). Data on treatment discontinuation (due to adverse events or lack of efficacy) and 
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adverse events were extracted as rates or number of cases. Only between-participant data from 
cross-over trials were included in the meta-analyses.  
 
Quality assessment 
Risk of bias was assessed by two independent raters (R.Z.M. and L.A.D.) using the Cochrane 
Collaboration’s tool for assessing risk of bias (20). The tool classifies the risk of bias in random 
sequence generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective reporting and other sources of bias as 
low, unclear or high (20).  
 
Data synthesis and analysis 
As included trials reported measures of pain and physical function using different scales, the 
results are presented as standardized mean differences (SMD) and 95% confidence intervals (95% 
CI). We considered a standardised effect size of 0.2 to represent a small effect, 0.5 as a moderate 
effect, and 0.8 as a large effect (21). Data regarding quality of life was reported using normalized 
versions of the Short-Form 36 (SF-36) across included trials and, therefore, results for this 
outcome are presented as mean differences (MD) and 95% CIs.  
 
Outcomes were grouped according to: a) follow-up time: immediate-term (less than two weeks), 
short-term (between two weeks and three months), intermediate-term (between three and 
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twelve months) or long-term (more than twelve months); and b) source of pain: back pain vs. hip 
and knee osteoarthritis pain.  
 
When there were multiple comparisons (i.e. multiple drugs or multiple dosages of the same drug) 
in a single study, the number of participants in the placebo group was divided by the number of 
comparisons (20). Pooled analyses were conducted using random effects model and I2 statistic 
was used to assess heterogeneity between trials (22). Meta-analyses were conducted using 
RevMan review management software (version 5.3, Biostat). Meta-regression analyses were 
conducted in Stata v13 (Stata Corp, College Station, TX). 
 
The  quality of evidence for each outcome was assessed using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) approach (23). The quality of evidence was 
downgraded by one or two levels according to the following criteria: (i) study limitations (when 
most of information is from studies at moderate or high risk of bias) (24), (ii) inconsistency of 
results (statistically significant heterogeneity [I2 >50%] or ≤75% of trials with findings in the same 
direction) (25), (iii) imprecision (wide confidence intervals or total number of participants <400 
for each pooled analysis) (26) and (iv) publication bias (assessed using funnel plot analysis and 
Egger test) (27). The indirectness criterion was not assessed because this review included a 
specific population with relevant outcomes and direct comparisons (28). The quality of evidence 
was defined as: high, moderate, low, and very low.   
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Post-hoc analyses 
We conducted a meta-regression to determine the association between the log-transformed 
morphine equivalent dose and the size of treatment effects on pain or function. The morphine 
equivalent dose was calculated according to the Consortium to Study Opioid Risk and 
Therapeutics (CONSORT) morphine equivalent conversion factor per milligram of opioid (29), and 
the European Palliative Care Research Collaboration (30). For tapentadol conversion, we 
considered morphine 10 mg equivalent to oral tapentadol 33 mg (31). When reported, the mean 
daily dose in the opioid group was used to calculate the daily dose in oral morphine equivalent. 
In trials where participants could use a range of capsules or patches and the mean daily dose of 
opioid was not reported (n=10), we estimated the mean daily dose from the range reported. We 
also conducted a meta-regression to determine the association between the treatment duration 
and the size of treatment effect on pain and function. 
 
Results 
The studies selection process is summarized in Figure 1. The initial search strategy retrieved 9940 
studies whose titles were screened for eligibility after duplicates were removed, leading to 292 
studies for abstracts review. This resulted in the assessment of 120 full-texts for eligibility. Of 
these, 25 randomised placebo-controlled trials of opioid analgesics for musculoskeletal pain in 
populations with mean age of 60 years and over were included in this review (a total of 6,455 
participants). The characteristics of the included studies are summarized in Table 1. Two of the 
included trials used a cross-over design but failed to provide between-participant data (32, 33). 
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Data from these two trials were not included in the meta-analyses. The duration of treatment 
ranged from 10 days to 24 weeks across the trials. Only immediate post-treatment data (i.e. 
within 14 days from end of intervention) were reported in included randomised controlled trials. 
The mean daily dose of opioid, in oral morphine equivalents, ranged from 10 to 300 mg morphine 
equivalents. 
 
The methodological quality assessment of each included studies is shown in supplementary 
figure S1. Overall, studies were of good quality and the risk of attrition bias was the major concern 
given that the rate of participants’ withdrawal was high (more than 20%) in all but one clinical 
trial. The quality of the evidence for each of the outcomes of interest is shown in Table 2, as well 
as the reason for downgrading the evidence. 
 
Efficacy Analysis 
Pain intensity 
From 24 trials that assessed the effects of opioid analgesics on pain intensity, only 16 provided 
enough data to be included in the meta-analysis. There is moderate quality evidence from 4,998 
participants that opioid analgesics decrease musculoskeletal pain (SMD: -0.27; 95% CI: -0.33 to -
0.20), when compared to placebo (Table 2 and Supplementary Figure S3).  
 
According to the musculoskeletal condition, there is moderate quality evidence from 13 studies 
(4565 participants) of a small effect of opioid analgesics on relieving hip or knee osteoarthritis 
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pain (SMD: -0.26; 95%CI: -0.33 to -0.19), and low quality evidence from 2 studies (283 
participants) on relieving back pain (SMD: -0.34; 95% CI: -0.59 to -0.09) (Figure 2).  
 
The meta-regression analysis showed that there is no association between daily doses (meta-
regression coefficient: -0.06; 95% CI: -0.14 to 0.01; p=0.107) or treatment duration (meta-
regression coefficient: 0.01; 95% CI: -0.07 to 0.19; p=0.369) and the size of treatment effect on 
pain. 
 
Function 
Fourteen trials assessed the effects of opioid analgesics on function but only 9 were included in 
the meta-analysis. There is moderate quality evidence from the included trials (2989 participants) 
of a small effect of opioid analgesics on function (SMD: -0.27, 95%CI: -0.36 to -0.18) (Table 2 and 
Supplementary Figure S4).  
 
Analyses were conducted also by specific musculoskeletal conditions, showing moderate quality 
evidence from 8 studies (2819 participants) of a small effect of opioid analgesics on improving 
disability due to hip or knee osteoarthritis (SMD -0.27; 95%CI: -0.36 to -0.17) (Table 2 and Figure 
3). There is very low quality evidence from a single study (170 participants) on disability 
improvements in patients with low back pain (SMD: -0.31; 95% CI: -0.61 to -0.01) (Table 2 and 
Figure 3).  
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Our meta-regression showed that daily doses (meta-regression coefficient: -0.05; 95% CI: -0.15 
to 0.05; p=0.273) or treatment duration (meta-regression coefficient: 0.02; 95% CI: -0.01 to 0.04; 
p=0.128) are not associated with the size of treatment effect on function. 
 
Quality of life 
Studies have reported the SF-36 physical and mental component summary score only in patients 
with hip or knee osteoarthritis (Table 2 and Supplementary Figure S5). There is low quality 
evidence from 6 studies (2478 participants) of an effect of opioid analgesics on the physical 
component of quality of life (MD: -1.49; 95% CI: -2.27 to -0.72; on a 1 to 100 scale) and very low 
quality evidence from 5 studies (2123 participants), of no effect of opioids on the mental 
component of quality of life (MD: 0.59; 95% CI: -0.31 to 1.54), compared to placebo. 
 
Safety Analysis  
Rate of adverse events 
Fourteen studies reporting the rate of participants who presented at least one adverse event 
during the trial were included in the meta-analysis (4288 participants). The most common 
adverse events reported were nausea, constipation, drowsiness, vomiting, dizziness, headache 
and dry mouth. There is very low quality evidence of an increase in the incidence of adverse 
events among participants allocated to the opioid treated groups (OR: 2.94; 95% CI: 2.33 to 3.72) 
(Table 2 and Figure 4).  
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Discontinuation due to adverse events or lack of efficacy 
Twenty-two studies reporting rates of participant withdrawal due to adverse events were 
included in the meta-analysis. There is moderate evidence from these studies (6368 participants) 
of an increased risk of discontinuation due to adverse events in participants allocated to opioid 
treated groups (OR: 4.04; 95% CI: 3.10 to 5.25) (Table 2 and Supplementary Figure S6).  
 
There is low quality evidence from 20 studies (5803 participants) that the allocation to an opioid 
group reduces the incidence of discontinuing treatment due to lack of efficacy by 63% (OR: 0.37; 
95% CI: 0.29 to 0.47) (Table 2 and Supplementary Figure S7).  
 
Discussion 
This systematic review suggests that the regular use of opioid analgesics (from 10 days to 24 
weeks) for older adults with musculoskeletal pain at daily doses from 10 to 300 mg of oral 
morphine equivalents results in only a small benefit in terms of pain and function. In addition, 
the risk of any adverse event is three times higher for opioid analgesics compared to placebo, 
and the rate of withdrawal due to adverse events is four times higher among older adults 
allocated to the opioid group compared to the placebo group. While this systematic review aimed 
to address the efficacy and safety of opioid analgesics specifically in older adults with 
musculoskeletal pain, the trials conducted to date that were included in this review had study 
populations with mean ages ranging from 60 to 72 years. Our findings are more applicable to 
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what would now be considered in developed countries “older” middle-aged adults rather than 
older people, letting alone frail older people as usual (34).  
 
We have found that the use of opioid analgesics in older adults resulted in only small benefits on 
pain relief compared to placebo. This benefit can be translated to a 6.8 mm decrease in pain 
intensity on a 100-mm visual analogue scale (VAS), on the basis of a median pooled SD of 25 mm 
found in 167 osteoarthritis trials using the same scale (15). Our findings are consistent with a 
magnitude of treatment effect found in previous systematic reviews of opioid analgesics for OA 
(14) and back pain (17) in younger populations.  
 
The effect of opioid analgesics on function and quality of life was also small. We found an effect 
equivalent to 0.56 units on a 0-10 point WOMAC disability subscale, on basis of a median pooled 
SD of 2.1 found in osteoarthritis trials that assessed pain using same scale (15). While the 
American Geriatrics Association recommends the use of opioid analgesics in older adults with 
pain-related functional impairment or diminished quality of life due to pain (1), our results 
suggest that analgesic opioids have only a small effect on these outcomes. Interestingly, the 
effect of opioids on pain or function does not seem to vary for different classes of opioids, 
prescribed at different daily doses or even for different painful musculoskeletal conditions.  
 
Our systematic review also showed the potential risk associated with taking opioid analgesic for 
musculoskeletal pain. The small benefits in terms of pain and function may be outweighed by the 
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increased risk of harm. We might have found even higher adverse events in the opioid group 
compared to placebo group, had the study samples been older.  
 
The strengths of this systematic review is that the pooled analyses results are based on 
randomized placebo-controlled clinical trials found using a comprehensive search strategy. 
Individual studies were assessed for validity and the GRADE approach was used to grade the 
quality of evidence and the strength of our recommendations. In addition, this systematic review 
was prospectively registered and we strictly followed all Cochrane’s recommendations for 
systematic review of interventions (20). A limitation was that we used aggregated data rather 
than individual participant data in the pooled analyses.  
 
For all conclusions drawn from our meta-analysis, the quality of evidence based on GRADE 
criteria was moderate or lower. The main reason for downgrading of GRADE rating was study 
bias more commonly due to high risk of attrition bias due to a higher withdrawal rate. Regardless 
of this limitation, the finding that opioid analgesics have only a modest effect on musculoskeletal 
pain may not justify the risks imposed by these drugs in older populations. Our finding would 
support the view that given opioids are of limited benefit, non-pharmacological approaches need 
to be emphasized in the management of persistent musculoskeletal pain in older adults  (36). 
The growing understanding that no currently available analgesic class is highly efficacious in 
achieving adequate pain relieve without the risk of major side effects is a key step towards a 
wider use of non-pharmacological strategies (37).  
97 
 
 
 
Acknowledgments  
RM was supported by Fundacao Hospitalar do Estado de Minas Gerais (FHEMIG) during his 
Masters of Philosophy.  
MLF holds a Sydney Medical Foundation Fellowship/Sydney Medical School. 
AJM is the Program Director of the NHMRC Centre for Research Excellence on Medicines and 
Ageing.  
 
Conflicts of Interest 
AJM is an investigator on the PACE trial funded by the National Health and Medical Research 
Council of Australia and GlaxoSmithKline (ACTRN 12609000966291), PRECISE trial funded by the 
National Health and Medical Research Council of Australia with in kind research support from 
Pfizer (ACTRN12613000530729) and the OPAL trial funded by the National Health and Medical 
Research Council of Australia (ACTRN12615000775516). 
 
98 
 
 
 
Table 1. Characteristics of included studies 
Source Baseline population Intervention Length of 
treatment 
Outcomes Eligible outcome 
measures 
Main findings Industry 
funding 
Arai et al., 
2015 (38) 
150 participants with 
chronic MSK pain (OAa 
or LBPb) and previous 
use of non-opioid 
analgesics. Mean age: 
66.3 years in the opioid 
group and 66.6 years in 
the placebo group 
Fentanyl transdermal 
12.5 - 50 mcg/h 
(n=73) or placebo 
(n=77). Mean daily 
opioid dose: 25.63 
mcg/h 
12 weeks Primary outcome: number of 
days until withdrawal because 
of insufficient analgesic 
efficacy. Secondary outcomes: 
change in VASc score in the 
double-blind period, subject's 
overall assessment score, 
number of times rescue 
medication was used, BPI-SFd 
score, SFe-36v2 physical and 
emotional scores, and 
physician's overall assessment 
score 
Pain intensity: VAS 0-100; 
Quality of life: SF-36 - 
PCSf and MCSg scores; 
rate of AEh; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
fentanyl transdermal 
superior to placebo 
(p=0.0215). 
SF-36 PCS: NSi 
SF-36 MCS: NS 
Yes 
(Janssen) 
Babul et al., 
2004 (39) 
246 participants with 
chronic pain due to knee 
OA that had warranted 
treatment for at least 75 
of 90 days prior to the 
study. Mean age: 61.2 
(10.0) years in the 
opioid group and 61.5 
(10.2) years in the 
placebo group 
Tramadol ER 200 - 
400 mg/day (n=124) 
or placebo (n=122) 
12 weeks Analgesia evaluated by the 
Arthritis Pain Intensity VAS and 
by the WOMACj OA Index pain 
subscale, improvements in 
physical function and stiffness 
evaluated by the WOMAC OA 
Index, and effects on sleep 
evaluated by the CPSIk 
Pain intensity : Arthritis 
Pain Intensity VAS (0-
100); Disability: WOMAC 
physical function subscale 
(0-1700); rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol superior to 
placebo (p<0.001). 
Disability: tramadol 
superior to placebo 
(p<0.001) 
Unclear 
Breivik et 
al., 2010 
(40) 
199 participants with 
chronic pan due to hip 
or knee OA who were 
taking NSAIDsl or coxibs 
one month prior to the 
screening visit. Mean 
age: 62.9 (9.9) years in 
the opioid group and 
62.9 (9.0) years in the 
placebo group 
Buprenorphine 
transdermal 5 - 20 
mcg/h (n=100) or 
placebo (n=99) 
24 weeks Primary outcome: change in 
WOMAC OA Index pain sub 
scale from the baseline to the 
end of the 6-month double-
blind period. Secondary 
outcomes: changes in WOMAC 
stiffness, physical function and 
total scores, daily rescue 
medication used, number of 
nights woken because of pain, 
and Patient's Global Impression 
of Change (PGIC) 
Pain intensity: WOMAC 
LK 3.1 – pain subscale (0-
20); Disability: WOMAC 
LK 3.1 – functional ability 
subscale (0-96); rate of 
AE; discontinuation due 
to AE; discontinuation 
due to lack of efficacy 
Pain intensity: NS 
Disability: NS 
Yes 
(Norpharma 
and 
Mundipharma) 
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Burch et al., 
2007 (41) 
646 participants with 
persistent pain due to 
knee OA who were 
taking NSAIDs, coxibs or 
tramadol one month 
prior to the enrolment. 
Mean age: 62 (9) years 
in the opioid group and 
62 (9) in the placebo 
group 
Tramadol Contramid 
OAD 200 - 300 
mg/day (n=432) and 
placebo (n=214). 
Mean daily opioid 
dose: 275.4 mg 
12 weeks Primary outcome: score on the 
PI - NRSm after 12 weeks of 
double-blind treatment. 
Secondary outcomes: 
percentage of patients who 
experienced an improvement 
of one to five in the PI-NRS, 
patient's and physician's global 
impressions of change 
Pain intensity : PI-NRS (0-
10); discontinuation due 
to AE; discontinuation 
due to lack of efficacy 
Pain intensity: 
tramadol superior to 
placebo (p<0.001) 
Unclear 
Caldwell et 
al, 2002 (42) 
295 participants with 
moderate-to-severe 
pain due to hip or knee 
OA on treatment with 
NSAIDs, acetaminophen 
or intermittent opioid 
analgesic therapy. Mean 
age > 60 years in all 
groups. 
Once-daily morphine 
(Avinza) 30 mg QAM 
(n=73), Once-daily 
morphine (Avinza) 30 
mg QPM (n=73), 
morphine sulphate 
controlled-release 
(MS Contin) 30 
mg/day (n=76) or 
placebo (n=73) 
4 weeks Primary outcomes: analgesia 
evaluated by WOMAC OA Index 
pain - sub scale and Overall 
Arthritis Pain Intensity scores. 
Secondary outcomes: WOMAC 
physical function and stiffness, 
and the effects of treatment on 
sleep 
Pain intensity: Overall 
Arthritis Pain Intensity (0-
100);  Disability: WOMAC 
physical function subscale 
(0-1700); discontinuation 
due to AE; 
discontinuation due to 
lack of efficacy 
Pain intensity: Avinza 
QAM, Avinza QPM 
and MS Contin 
superior to placebo 
(p<0.05) when 
analgesia evaluated 
by WOMAC OA Index 
Pain 
Disability: NS 
Unclear 
DeLemos et 
al. 2011 (43) 
1011 participants with 
moderate-to-severe 
pain due to hip or knee 
OA that had warranted 
treatment for at least 75 
of 90 days prior to the 
study. Mean age of 60 
years. 
Tramadol ER in 
different doses: 100 
(n=202), 200 (n=203) 
or 300 mg/day 
(n=201), Celecoxib 
(n=203 or placebo 
(n=202) 
12 weeks Primary outcomes: 
improvements in WOMAC pain 
and physical function sub 
scales, and patient's global 
assessment of disease activity. 
Secondary outcomes: reduction 
in daily arthritis pain intensity, 
WOMAC stiffness sub scale and 
composite index, physician's 
global assessment, SF-36 and 
overall quality of sleep 
Pain intensity: WOMAC 
Pain subscale (0-500);  
Disability: WOMAC 
physical function subscale 
(0-1700); Quality of life: 
SF-36 PCS; rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol 100 mg vs. 
placebo: NS; tramadol 
200 mg vs. placebo: 
NS; tramadol 300 mg 
vs. placebo: NS; 
Disability: tramadol 
100 mg vs. placebo: 
NS; tramadol 200 mg 
vs. placebo: NS; 
tramadol 300 mg vs. 
placebo: NS; 
Yes  
(Biovail and 
Ortho-McNeil 
Janssen) 
Emkey et al. 
2004 (44) 
306 participants with 
symptomatic OA of the 
knee or hip for more 
than 1 year (at least 
moderate pain) despite 
treatment with coxibs 
for at least 2 weeks 
preceding the study. 
Tramadol/ 
acetaminophen 
(Ultracet) 150 - 300 
mg/day (n=153) or 
placebo (n=153). 
Mean daily opioid 
dose: 154 mg/day 
13 weeks Primary outcome: 
improvements in pain VAS 
scores. secondary outcomes: 
pain relief scores, patient's and 
physician's overall medication 
assessment, time to 
discontinuation due to lack of 
efficacy, proportion of subjects 
Pain intensity: VAS (0-
100);  Disability: WOMAC 
physical function subscale 
(0-10); Quality of life: SF-
36 PCS and MCS scores; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol superior to 
placebo (p=0.025). 
Disability: tramadol 
superior to placebo 
(p=0.049) 
SF-36 PCS: NS 
SF-36 MCS: NS 
Unclear 
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Mean age: 60.1 (9.08) 
years in the opioid 
group and 61.8 (8.84) in 
the placebo group 
discontinuing due to lack of 
efficacy, WOMAC and SF-36 
scores 
Fishman et 
al., 2007 
(45) 
520 participants with 
pain due to knee OA. 
Mean age of 63 (8), 61 
(9) and 60 (9) years in 
the opioid groups and 
61 (10) years in the 
placebo group. 
Tramadol Contramid 
OAD 100 mg (n=103), 
200 mg (n=107) or 
300 mg/day (n=105) 
or placebo (n=224). 
12 weeks Patients' Global Rating of Pain 
Relief, WOMAC pain sub scale 
and WOMAC physical function 
sub scale 
Pain intensity: WOMAC 
Pain subscale (0-500);  
Disability: WOMAC 
physical function subscale 
(0-1700); rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol 100 mg vs. 
placebo: NS; tramadol 
200 mg vs. placebo: 
p=0.05); tramadol 
300 mg vs. placebo: 
p=0.016; 
Disability: tramadol 
100 mg vs. placebo: 
p=0.0268; tramadol 
200 mg vs. placebo: 
p=0.0450; tramadol 
300 mg vs. placebo: 
p=0.0211; 
Yes 
(Labopharm) 
Fleischmann 
et al. 2001 
(46) 
129 participants with 
pain associated with 
knee OA. Mean age:  
62.5 (8.68) years in the 
opioid group and 62.45 
(9.62) years in the 
placebo group 
Tramadol 200 - 400 
mg/day (n=63) or 
placebo (n=66).  
13 weeks Primary outcome: pain 
intensity experienced in target 
knee within 48 hours before 
the final visit. Secondary 
outcomes: pain relief scores, 
patients and investigator 
overall assessments, WOMAC 
scores, and time to failure of 
effectiveness 
Pain intensity: Pain 
intensity score (0-4);  
Disability: WOMAC 
physical function subscale 
(0-10); discontinuation 
due to AE; 
discontinuation due to 
lack of efficacy 
Pain intensity: 
tramadol superior to 
placebo (p=0.045, t 
test / p=0.082, 
ANCOVA) 
Disability: tramadol 
superior to placebo 
(p=0.033) 
Yes 
(Ortho-McNeil) 
Hyup Lee et 
al., 2013 
(47) 
248 participants with 
moderate to severe 
chronic low back pain 
despite the use of 
NSAIDs or coxibs. Mean 
age: 60 years 
Extended release 
tramadol/ 
paracetamol 
(Ultracet ER) 150 - 
300 mg/day (n=125) 
or placebo (n=120) 
29 days Primary outcome: percentage 
of patients with a pain intensity 
change rate > 30%. Secondary 
outcomes: pain relief, quality of 
life and functionality 
measurements, and patients 
and investigator global 
assessment of treatment 
Pain intensity: VAS (0-
100);  Disability: Korean 
Oswestry Disability Index 
(0-100); Quality of life: 
Korean SF-36; rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol/ 
paracetamol superior 
to placebo (p=0.0095) 
Disability: tramadol/ 
acetaminophen 
superior to placebo 
(p=0.0449) 
Yes  
(Janssen) 
Kivitz et al., 
2006 (48) 
370 participants with 
symptomatic knee or hip 
OA who had been taking 
acetaminophen, NSAIDs 
or opioid analgesics for 
Oxymorphone 
extended release 20 
mg (n=95), 80 mg (n= 
93) or 100 mg/day 
2 weeks Primary outcome: mean 
change in arthritis pain 
intensity. Secondary outcomes: 
change in WOMAC sub scales, 
physical health component 
Pain intensity: Arthritis 
Pain Intensity - VAS (0-
100);  Disability: WOMAC 
physical function subscale 
(0-1700); Quality of life: 
Pain intensity: 
oxymorphone 20 mg 
BID vs. placebo: NS; 
oxymorphone 40 mg 
BID vs. placebo: 
Yes 
(Endo 
Pharmaceutics) 
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90 days before the 
screening visit. Mean 
age: 63 (10.9), 62 (11.5) 
and 62 (11.4) years in 
the opioid groups and 
60 (11.2) years in the 
placebo group 
(n=91) or placebo 
(n=91) 
summary of SF-36 and quality 
of sleep 
SF-36 PCS score; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
p=0.012; 
oxymorphone 50 mg 
BID vs. placebo: 
p=0.006; 
Disability: 
oxymorphone 20 mg 
BID vs. placebo: 
p<0.025; 
oxymorphone 40 mg 
BID vs. placebo: 
p<0.01; oxymorphone 
50 mg BID vs. 
placebo: p<0.01; 
SF-36 PCS score: 
oxymorphone in all 
doses superior to 
placebo (p<0.001) 
 
Langford et 
al., 2006 
(49) 
416 participants with 
chronic pain due to hip 
or knee OA and 
requiring joint 
replacement surgery. 
Mean age: 66 (0.7) 
years. 
Fentanyl transdermal 
25-100 mcg/h 
(n=202) or placebo 
(n=197). Mean daily 
opioid dose: 42.5 
mcg/h 
6 weeks Primary outcome: pain relief 
expressed as the difference in 
the average AUCn of the VAS 
scores (pain diary) over the 
time. Secondary outcomes: 
function assessed by WOMAC 
score and individuals aspects of 
pain affecting mobility and 
quality of life (SF-36 scores) 
Pain intensity: VAS (0-
100);  Disability: WOMAC 
physical function subscale 
(0-10); Quality of life: SF-
36 PCS and MCS scores; 
rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
fentanyl transdermal 
superior to placebo 
(p=0.025). 
Disability: NS 
SF-36 PCS: NS 
SF-36 MCS: fentanyl 
transdermal inferior 
to placebo (p=0.041) 
Yes 
(Janssen-Cilag) 
Malonne et 
al., 2004 
(50) 
230 participants with 
pain due to hip or knee 
OA requiring regular 
treatment with 
analgesics for more than 
1 month. Mean age of 
67.1 (7.1) for the opioid 
group and 66.4 (9.2) for 
the placebo group 
Sustained-release 
tramadol 200 
mg/day (n=111) or 
placebo (n=119) 
2 weeks Primary outcome: change in 
the global pain score from the 
baseline to the end of the 
study. Secondary outcomes: 
Lequesne functional discomfort 
index, patient's and 
investigator's assessment of 
global efficacy, time to 
improvement, and use of 
rescue medication 
Pain intensity: VAS (0-
100); Disability: Lequesne 
functional discomfort 
index (0-20); rate of AE; 
discontinuation due to 
AE. 
Pain intensity: 
tramadol superior to 
placebo (p=0.010). 
Disability: NS 
 
Unclear 
Markenson 
et al., 2005 
(51) 
107 participants with OA 
(defined by ACR 
guidelines) and 
Controlled-release 
oxycodone (CR 
Oxycontin) 20 - 120 
90 days Primary outcome: Brief Pain 
Inventory (BPI) average pain 
intensity at stable dosing, 
Pain intensity: BPI (0-10);  
Disability: WOMAC 
physical function subscale 
Pain intensity: 
oxycodone superior 
to placebo (p=0.042). 
Yes 
(Purdue 
Pharma) 
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moderate-to severe pain 
requiring regular 
treatment with NSAIDs, 
acetaminophen or 
intermittent opioid 
therapy for at least 2 
weeks prior to the 
study. Mean age of 62 
(38.8) years in the 
opioid group and 64 
(41.89) years in the 
placebo group. 
mg/day (n=56) or 
placebo (n=51). 
Mean daily opioid 
dose: 44 mg/day) 
WOMAC scores at days 30 and 
60 and number of patients who 
discontinued the study due to 
inadequate pain control. 
Secondary outcomes: BPI, 
WOMAC, PGIo scores, time to 
stable dosing, average daily 
dose, patient-reported 
acceptability of and satisfaction 
with medication, ratings of 
average and current pain 
intensity from patients diary 
(0-1700); Quality of life: 
SF-36 PCS and MCS 
scores; rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Disability: oxycodone 
superior to placebo 
(p<0.001) 
 
Markman et 
al., 2015 
(32) 
24 participants with 
neurogenic claudication 
associated with lumbar 
stenosis and mean age 
of 71.8 years. 
Oxymorphone 5 mg, 
propoxyphene/ 
paracetamol 100 mg 
or placebo 
Single 
dose 
Primary outcome: time to first 
reported pain of moderate 
intensity during a treadmill 
test. Secondary outcomes: pain 
at rest before starting the test, 
area under the pain-intensity 
curve, pain intensity after 15 
minutes, time and distance 
walked in the treadmill, and 
time to return to baseline pain. 
Other outcome measures 
assessed 45 minutes after the 
treatment: global assessment 
of low back pain, RMDQp, BPI, 
Oswestry Disability Index, Swiss 
Spinal Stenosis Questionnaire 
Pain intensity: Pain at rest 
(0-10) measured 90 
minutes after study drug 
in each period 
Pain intensity: NS 
Study was stopped 
early because 
propoxyphene/ 
acetaminophen was 
removed from the 
United States market 
due to evidence of 
adverse cardiac 
effects   
Yes 
(Endo 
Pharmaceutics) 
Matsumoto 
et al., 2005 
(52) 
491 participants with 
typical hip or knee OA 
symptoms that had 
warranted treatment for 
at least 75 of 90 days 
prior to the study. Mean 
age: 61.4 (1.0), 63.4 
(0.9) and 62.7 (1.0) 
years in the opioid 
groups and 61.7 (1.0) 
years in the placebo 
group 
Oxymorphone 
extended-release 20 
mg BID (n=121), 40 
mg BID (n=121), 
oxycodone 20 mg 
BID (n= 125) or 
placebo (n=124) 
4 weeks Primary outcome: changes in 
Arthritis Pain Intensity (API) 
score from baseline to the 
week 3 visit in the 
oxymorphone 40 mg group 
compared with that in placebo 
group. Secondary outcomes: 
comparison with oxymorphone 
20 mg, WOMAC OA index, 
patient's and physician's global 
assessments of therapy, 
withdrawal due to lack of 
Pain intensity: VAS (0-
100);  Disability: WOMAC 
physical function subscale 
(0-10); Quality of life: SF-
36 PCS and MCS scores; 
rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
oxymorphone 40 mg 
BID vs placebo: 
p=0.0015; 
oxymorphone 20 mg 
BID vs placebo: 
p=0.039; oxycodone 
20 mg BID vs placebo: 
NS 
Disability: 
oxymorphone 40 mg 
Yes 
(Endo 
Pharmaceutics) 
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efficacy, quality of sleep and 
quality of life (SF-36) 
BID vs placebo: 
p<0.05; 
oxymorphone 20 mg 
BID vs placebo: 
p<0.05; oxycodone 20 
mg BID vs placebo: NS 
Munera et 
al., 2010 
(53) 
315 men and women 
with hip or knee OA 
whose pain was 
inadequately controlled 
with NSAIDs ibuprofen 
1,600 mg/day). Mean 
age population: 60 years 
in the opioid group and 
62 in the placebo group 
Buprenorphine 
transdermal system 
(BTDS) 5-20 mcg/h 
(n=152) or placebo 
(n=163) 
4 weeks Primary outcome: percentage 
of patients who achieved 
treatment success (patient 
satisfaction scale 2 or more on 
a 5-point scale). Secondary 
outcomes: average pain 
intensity score, patient's 
satisfaction with study 
medication score, and a weekly 
average of diary pain score 
Pain intensity: 11-point 
pain scale (0=no pain and 
10=worst pain you can 
imagine); rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: NS  
(however, more 
buprenorphine 
treated patients 
experienced 
treatment success 
than placebo) 
Yes 
(Purdue 
Pharma) 
Peloso et al. 
2000 (54) 
103 participants with hip 
or knee OA requiring 
acetaminophen, NSAIDs 
or opioids for the 
previous 3 months, who 
experienced a flare 
during the washout 
period. Mean age:  60.1 
(11.4) years in the 
opioid group and 63.0 
(10.9) years in the 
placebo group. 
Controlled release 
codeine 100 - 400 
mg/day (n=51) or 
placebo (n=52). 
Mean daily opioid 
dose: 317.8 mg 
4 weeks Primary outcomes: WOMAC 
pain VAS and daily overall Pain 
Intensity scores over the 
previous week. secondary 
outcomes: WOMAC stiffness 
and physical sub scales, daily 
VAS average pain scale, 7 item 
questionnaire on sleep, Drug 
Liking Index 
Pain intensity: Weekly 
pain intensity - VAS (0-
100); Disability: WOMAC 
physical function subscale 
(0-1700); rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
codeine superior to 
placebo (p=0.0001) 
Disability: codeine 
superior to placebo 
(p=0.0007) 
Unclear 
Roth, 1998 
(35) 
42 participants on stable 
NSAIDs therapy who 
experienced 
breakthrough 
musculoskeletal pain 
attributed to OA. Mean 
age: 67 years in the 
opioid group and 65.9 in 
the placebo group. 
Tramadol HCl 50 - 
400 mg/day (n=21) 
or placebo (n=21) 
2 weeks Primary outcome: time to exit 
from the study because of 
therapeutic failure. Secondary 
outcome: severity of pain at 
rest, severity of pain on 
motion, severity of current 
pain, patient's ability to 
perform activity of daily living 
and patient's overall 
assessment of therapy 
Pain intensity on motion: 
4-point severity of pain 
score (0=none and 
3=severe); Disability: ADL 
score (0-3); 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol superior to 
placebo on pain at 
rest (p=0.046) but not 
on pain in motion 
(p=0.059). 
No significant 
differences in ability 
to perform activities 
of daily living 
Yes 
(Ortho-McNeil) 
Roth et al. 
2000 (55) 
133 participants with 
moderate-to-severe OA-
Controlled-release 
oxycodone 10 mg 
2 weeks Primary outcome: daily mean 
pain intensity. Secondary 
Pain intensity: 4-point 
pain intensity scale 
Pain intensity: only 
oxycodone 20 mg BID 
Unclear 
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related pain. Mean age: 
62 (2) and 63 (2) years in 
the opioid groups and 
62 (2) in the placebo 
group 
BID (n=44), 20 mg 
BID (n=44) or 
placebo (n=45) 
outcomes: quality of sleep, BPI, 
interference of pain and ability 
to perform 8 daily activities 
(0=none and 3=severe); 
Disability: 4-point ADL 
score (1=without any 
difficulty to 4=unable to 
do); discontinuation due 
to AE; discontinuation 
due to lack of efficacy 
significantly superior 
to placebo 
Disability: no 
significant differences 
between oxycodone 
10 or 20 mg BID and 
placebo   
Schnitzer et 
al., 1999 
(56) 
240 participants with 
pain due to knee OA in 
use of naproxen. Mean 
study age: 61.4 years 
Tramadol 200 
mg/day (n=117) or 
placebo (n=123) 
8 weeks Primary outcome: Minimal 
effective naproxen dose 
(MEND) 
Discontinuation due to 
adverse events 
Among participants 
stratified as naproxen 
responders, the 
MEND was 
significantly lower in 
patients receiving 
tramadol than in 
patients receiving 
placebo 
Yes 
(Ortho-McNeil) 
Silverfield et 
al., 2002 
(57) 
308 participants with 
symptomatic OA of the 
hip or knee who had 
been experiencing OA 
flare pain for 2 to 5 days 
on use of stable doses of 
NSAIDs or coxibs. Mean 
population age: 60 
(9.74) years in the 
opioid group and 60.4 
(10.12) in the placebo 
group. 
Tramadol-
paracetamol 
(Ultracet) 150 - 300 
mg/day (n=197) or 
placebo (n=111) 
10 days Primary outcome: average daily 
pain scores, average pain relief 
scores for days 1 to 5. 
Secondary outcomes: dose 
response (SPRID), patient's and 
investigator's overall 
assessments, WOMAC scores 
Pain intensity: WOMAC 
pain subscale (0-10); 
Disability: WOMAC 
physical function subscale 
(0-12.5); rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol superior to 
placebo (p=0.004) 
Disability: tramadol 
superior to placebo 
(p=0.013) 
Unclear 
Thorne et 
al., 2008 
(33) 
100 participants with 
symptomatic hip or knee 
OA, on acetaminophen, 
NSAIDs or combination 
opioid and non-opioid 
analgesics for at least 3 
months and at least 
moderate pain at the 
time of enrolment. 
Mean age of 61 (10.3) 
years. 
Controlled-release 
tramadol 150 to 400 
mg/day (n=50), or 
placebo (n=50). 
Mean daily opioid 
dose: 340.3 (90.7) 
mg 
8 weeks - 
4 weeks 
each for 
period of 
treatment 
Primary outcome: VAS pain 
intensity from the patients' 
daily diaries averaged over the 
last week of treatment. 
Secondary outcomes: WOMAC 
scores, PDI, Pain and Sleep 
Questionnaire, SF-36, 
treatment effectiveness and 
treatment preference 
Pain intensity: VAS (0-
100); Disability: WOMAC 
physical function subscale 
(0-1700); Quality of life: 
SF-36 - PCS and MCS 
scores; rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Pain intensity: 
tramadol superior to 
placebo (p=0.0009) 
Disability: tramadol 
superior to placebo 
(p=0.0205) 
SF-36 PCS: tramadol 
superior to placebo 
(p=0.0002) 
SF-36 MCS: NS 
Yes 
(Purdue 
Pharma) 
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Vorsanger 
et al., 2013 
(58) 
108 participants with 
symptomatic vertebral 
compression fractures. 
Mean study age: 69.8 
(12.28) years in the 
tapentadol group, 69.3 
(13.26) years in the 
oxycodone group and 
69.6 (12.36) years in the 
placebo group 
Tapentadol IR 200-
450 mg/day (n=44), 
oxycodone IR 20-60 
mg/day (n=43) or 
placebo (n=21) 
10 days Primary outcome: sum of pain 
intensity difference (SPID) over 
72 hours. Secondary outcomes: 
total pain relief (TOTPAR) and 
sum of pain relief and intensity 
differences (SPRID) 
Pain intensity: SPID (0-
10); rate of AE; 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy 
Insufficient statistical 
power for 
comparative efficacy 
analysis – trial was 
stopped due to slow 
enrolment  
Yes 
(Janssen) 
Zautra et 
al., 2005 
(59) 
107 participants with OA 
(defined by the ACRq) 
and moderate-to-severe 
pain. Mean population 
age: 62.6 years in the 
opioid group and 63.9 
years in the placebo 
group 
Controlled-release 
oxycodone 20 - 120 
mg/day (n=56) or 
matching placebo 
(n=51) 
90 days Average daily pain intensity, 
changes in positive and 
negative affect scales, 
Vanderbilt Multidimensional 
Pain Coping Inventory, copping 
efficacy and arthritis helpless 
Pain intensity: average 
24h pain - 0-10 (0=no 
pain to 10=pain as bad as 
you can imagine); 
discontinuation due to 
AE; discontinuation due 
to lack of efficacy  
Pain intensity: 
oxycodone superior 
to placebo (p<0.001) 
Yes 
(Purdue 
Pharma) 
a Osteoarthritis 
b Low back pain 
c Visual Analog Scale 
d Brief Pain Inventory Short Form 
e Short Form 
f Physical Component Summary 
g Mental Component Summary 
h Adverse events 
i Non significant 
j Western Ontario and McMaster Universities Osteoarthritis Index 
k Chronic Pain Sleep Inventory 
l Nonsteroidal anti-inflammatory drugs 
m Pain intensity – Numerical Rating Scale 
n Area under the curve 
o Patient Generated Index 
p Roland-Morris Disability Questionnaire 
q American College of Rheumatology 
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Figure 1. Summary of the search process.  
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Figure 2. Effect of opioid on pain intensity according to the site of pain: back pain or hip or 
knee osteoarthritis 
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Figure 3. Effect of opioid on function according to the site of pain: back pain or hip or knee 
osteoarthritis 
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Figure 4. Risk of adverse events – opioid vs. placebo 
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Table 2. Summary of findings: opioid analgesics compared with placebo for older adults with 
musculoskeletal pain 
 
 
Outcomes No of Participants 
(studies) 
Quality of the evidence 
(GRADE) 
Comments 
Pain intensity (follow-up) - 
Immediate-term 
Different scales 
Follow-up: 10-168 days 
4998 
(16 studies) 
⊕⊕⊕⊝ 
moderate1 
SMD -0.27 (-0.33 to -0.2) 
Pain intensity (source of 
pain) - Low back pain 
Different scales 
Follow-up: 10-29 days 
283 
(2 studies) 
⊕⊕⊝⊝ 
low1,2 
SMD -0.34 (-0.59 to -0.09) 
Pain intensity (source of 
pain) - Hip or knee OA 
Different scales 
Follow-up: 14-168 
4565 
(13 studies) 
⊕⊕⊕⊝ 
moderate1 
SMD -0.26 (-0.33 to -0.19) 
Function (follow-up) - 
Immediate-term 
Different scales 
Follow-up: 14-168 days 
2989 
(9 studies) 
⊕⊕⊕⊝ 
moderate1 
SMD -0.27 (-0.36 to -0.18) 
Function (source of pain) - 
Low back pain 
Oswestry 
Follow-up: 29 days 
170 
(1 study) 
⊕⊝⊝⊝ 
very low2,3 
SMD -0.31 (-0.61 to -0.01) 
Function (source of pain) - 
Hip or knee OA 
Different scales 
Follow-up: 14-168 days 
2819 
(8 studies) 
⊕⊕⊕⊝ 
moderate1 
SMD -0.27 (-0.36 to -0.17) 
QoL - Physical Component 
Summary (follow-up) - 
Immediate-term 
SF-36 
Follow-up: 14-90 days 
2478 
(6 studies) 
⊕⊕⊝⊝ 
low1,4 
MD -1.49 (-2.27 to -0.72) 
QoL - Mental Component 
Summary (follow-up) - 
Immediate-term 
SF-36 
Follow-up: 28-90 days 
2123 
(5 studies) 
⊕⊝⊝⊝ 
very low1,2,4 
MD 0.59 (-0.31 to 1.49) 
Rate of adverse events 
Follow-up: 10-168 days 
4288 
(14 studies) 
⊕⊝⊝⊝ 
very low1,4,5 
OR 2.94  
(2.33 to 3.72) 
Discontinuation due to AE 
Follow-up: 10-168 days 
6368 
(22 studies) 
⊕⊕⊕⊝ 
moderate1 
OR 4.04  
(3.1 to 5.25) 
Discontinuation - lack of 
efficacy 
Follow-up: 10-168 days 
5803 
(20 studies) 
⊕⊕⊝⊝ 
low1,5 
OR 0.37  
(0.29 to 0.47) 
1 Serious study limitations 
2 Imprecision 
3 Very serious study limitations 
4 Publication bias 
5 Inconsistency of results (I2 > 50%) 
 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may 
change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely 
to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
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5.1 Overview of principal findings 
The main aim of this thesis was to contribute to the current knowledge of how age-related 
conditions such as multimorbidity and frailty interact with musculoskeletal pain and its 
management. In order to achieve this aim, the thesis has focused on investigating the 
association between frailty and chronic musculoskeletal pain, and the role and effectiveness 
of pain medication for musculoskeletal conditions in this specific population.  
 
While previous studies have found that chronic pain is a significant risk factor for disability (1-
7), depressive symptoms (8) and decreased quality of life (9), its association with the risk of 
developing the frailty phenotype still needed to be elucidated. Therefore, the first aim of this 
thesis was to investigate whether musculoskeletal pain was an independent risk factor for the 
development of frailty in older men. Chapter Two demonstrated that chronic pain, i.e. daily 
pain for at least three months, was associated with an increased risk of developing the 
physical frailty phenotype, assessed using the CHS criteria, over 5 years. This finding suggests 
an important potential role for effective pain management in the prevention of further 
decline in physical function among older people. While randomized controlled trials have 
shown that nutritional supplementation, cognitive training and physical exercises 
intervention may prevent or reduce frailty (10-12), no trials have been conducted assessing 
the effects of pain management on frailty development. Likewise, current trials of pain 
management for older people have failed to include frailty as an outcome measure and 
therefore there is paucity of evidence on the impact of pain management on frailty.  
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The second aim of this thesis was to investigate whether frailty status was an independent 
risk factor for developing pain. Chapter Two has confirmed that pre-frail and frail older men 
were not at an increased risk of developing chronic or intrusive pain. Frailty has been 
associated with brain pathology, including macroinfarcts, senile plaques, neurofibrillary 
tangles and nigral neuronal loss (13), which might result in impaired descendent inhibitory 
pain modulation (14). This link provides a reasonable rationale for investigating whether 
frailty leads to pain of longer duration or greater severity. Although frailty was found to be 
associated with future intrusive pain in the CHAMP study, this association was confounded 
by other clinical features, particularly age, BMI, number of comorbidities and depression. The 
pathophysiology of pain is multifactorial and not completely understood, and our findings 
suggest that the relationship between frailty and pain cannot be solely attributed to frailty-
related changes of the brain. For instance, there is accumulated evidence that late-life 
depression and frailty are interrelated concepts that might share the same underlying 
pathology (15-17) and that may be the case for other commonly observed comorbidities in 
this age group.   
 
Although frailty has not proved to be a risk factor for developing pain, pain is still very 
prevalent among older adults (18-22). Unfortunately, evidence on the effectiveness of 
musculoskeletal pain management interventions in older people is scarce. As a result, 
clinicians need to rely on their own judgement and past experience to treat this condition. 
Therefore, the third aim of this thesis was to describe aspects of the current management of 
musculoskeletal pain in older adults in Australia. Chapter Three describes primary care 
management of vertebral compression fracture, a common and painful musculoskeletal 
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condition typically seen in older patients. The results confirm that primary care clinicians rely 
mostly on opioid analgesics, usually in low doses, to treat pain associated with vertebral 
fractures. Interestingly, prescriptions for “strong” opioid analgesics, i.e. opioid analgesics 
used for moderate-to-severe pain according to the World Health Organization three-step 
analgesic ladder (23), were more frequent in follow-ups than in first encounters for vertebral 
compression fractures, suggesting that the need for opioids did not decrease over time, as 
would be expected. This practice is problematic as many older adults with vertebral 
compression fractures remain on opioid analgesics long after an episode of acute pain 
typically resolves, increasing the risks of opioid-related side effects such as constipation, 
sedation, falls and physical dependence (24). The findings of the study reported in Chapter 
Three also suggest that referrals to allied health care have been unusual in general practice 
management of vertebral compression fractures. Although the evidence on the effectiveness 
of non-pharmacological treatment for this condition is scarce (25), a multidisciplinary team 
approach could contribute to pain management.  
 
A similar pattern of opioid analgesic prescription was also found in the United States, where 
a study showed that around 15% of older patients admitted to hospital are prescribed a new 
opioid analgesic before being discharged and around 40% of them are still in use of opioid 
analgesics 90 days later (26). This practice is likely reflective of the American Geriatric Society 
recommendations for the management of older patients with moderate to severe persistent 
pain (27). However, these recommendations do not seem to be derived from high quality 
evidence and it is currently still unknown whether the benefits of opioid analgesics overweigh 
their risks of adverse events, particularly in older patients. Therefore, the fourth and final aim 
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of this thesis was to systematically review and appraise the literature on the efficacy and 
safety of opioid analgesics for older adults with musculoskeletal pain. Chapter Four showed 
that regular use of opioid analgesics for musculoskeletal pain, at daily doses varying from 10 
to 300 mg of oral morphine equivalents, results in only a small benefit in terms of pain and 
function among older adults. In addition, the effect of opioid analgesics in these patients is 
not influenced by dosage or treatment duration. The risk of any adverse event, however, is 
three times higher in the opioid analgesics group, compared to placebo. This finding suggests 
that recommendations on prescription of opioid analgesics for musculoskeletal pain in older 
people should be re-evaluated, given that their modest effect on pain and function is probably 
not outweighed by their risks. Moreover, it reinforces the need for non-pharmacological 
strategies in chronic pain managements since even opioid analgesics alone have only a small 
benefit in chronic musculoskeletal conditions. Improving and promoting non-pharmacological 
pain management strategies may contribute in controlling the opioid epidemic that also 
affects older adults.  
5.2 Implications and directions for future research 
5.2.1 Pain and frailty 
The cohort study presented in Chapter Two reinforces the association between pain and 
frailty, and represents a step forward in understanding this association. It seems that chronic 
pain is a risk factor for developing frailty but frailty on its own is not a risk factor for developing 
chronic or intrusive pain in older men. Only one longitudinal study has previously assessed 
the association between chronic pain and frailty and they have also included data from a 
cohort of aged men (28). Therefore, to date, the longitudinal association between chronic 
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pain and frailty in women is still unknown, even though there is reason to believe that 
relationship would differ according to gender. For instance, frailty has been shown to be more 
prevalent among women, when compared to men (29), and this is partly because they have 
reduced lean mass and strength compared to age-matched men (30). Women also are at 
greater risk of developing a number of clinical pain conditions, including osteoarthritis and 
fibromyalgia, (31) that may lead to muscle wasting and disuse atrophy (32). Future studies 
should investigate the role of chronic pain as a risk factor for frailty across both genders.  
 
In addition, most older adults who experience chronic pain are long-term users of analgesic 
drugs.  However, the role of analgesic drugs use on the risk of developing frailty remains 
unclear. A cross-sectional population-based study found that the use of analgesics was 
positively associated with the severity of frailty, even after adjusting for presence of pain (33). 
Although it was suggested that pain management could be a potential strategy to prevent 
frailty, excessive opioid analgesics consumption could have an opposite effect. Future studies 
should investigate the relationship between analgesics consumption and risks of frailty in 
order to determine which pain management strategies could be beneficial and which of them 
could cause additional harm in older adults with musculoskeletal pain. 
 
The role of depressive symptoms and physical comorbidities in the association between frailty 
and the risk of intrusive pain is also a question that needs to be elucidated in the future. Pain 
usually co-occurs with core elements of the frailty phenotype, i.e. weight loss, exhaustion, 
weakness, slowness and low energy expenditure (34). It is possible that pain may result in, or 
be the result of, each one of the frailty criteria. There are, however, many clinical variables 
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that could be underlying such association. For instance, depressive symptoms, that are 
usually associated with chronic pain, are also associated with the CHS frailty criteria (15-17) 
and it is possible that depressive symptoms as well as other clinical conditions act as 
mediators in that relationship. Future studies should consider carrying out mediation analysis 
in order to identify and explain mechanisms underlying pain and frailty association. 
 
5.2.2 Pain management in older adults 
Chapters Three and Four are concerned with the management of older adults with 
musculoskeletal pain. Chapter Three concludes that primary care clinicians have become 
opioid-centred in treating vertebral compression fractures in older adults. Concerns around 
the rise in the prescription of opioids analgesics (35, 36) must be viewed in the context of 
global ageing and increased prevalence of chronic pain conditions. Clinicians have to deal with 
an increasing number of older patients with chronic pain who seek care with unrealistic 
expectations regarding the effectiveness of pharmacological treatments (37). Chronic 
musculoskeletal pain is a multidimensional condition (38) and it is unlikely that the use of 
analgesics alone will address all dimensions of this condition, particularly psychosocial and 
functional dimensions  (39-41). Rather, the combination of analgesics with non-
pharmacological approaches might result in better pain relief and improvement of function. 
Future clinical trials should assess the efficacy of multi-modal pain treatments including 
patient education, physical rehabilitative and psychological approaches, occupational 
therapy, analgesic drugs and regional anaesthesia, in older adults with musculoskeletal pain, 
particularly in those with chronic pain conditions. 
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Opioid analgesics have only a small effect on pain relief and disability as shown in Chapter 
Four, despite their growing popularity for the management of musculoskeletal pain in older 
adults. Opioids are also three times more likely to cause side effects, compared to placebo in 
this population. In general, however, the participants included in the identified trials were 
younger-old adults (i.e. those between 65 and 75 years old) and less likely to present with 
comorbidities, including frailty. Although older adults are now being enrolled in clinical trials, 
it seems that there remains a preference to include the young old. Possible reasons for not 
including older-old adults are challenges in gaining informed consent, risk of polypharmacy, 
challenges in compliances with the trial procedures and the belief that this subgroup will not 
respond to treatment (42). Unfortunately, exclusion and under-recruitment of older adults in 
clinical trials implies that many treatments currently in use by clinicians who deal with older 
and frail patients have not been appropriately evaluated. Clinical trials involving frail older 
patients are urgently needed as extrapolating results from trials including only robust 
individuals to an aged population might result in potentially harmful practices. 
 
The finding that opioid analgesics have only a small benefit in older populations with 
musculoskeletal pain is consistent across clinical trials using different opioid analgesics, in 
different doses, and for different musculoskeletal conditions. Although opioid analgesics 
could be a good option for selected patients, arguably they should not be the first line 
treatment for older adults in pain. Because older patients are at higher risk of adverse drug 
reactions, clinicians should start with non-opioid medications in combination with non-
pharmacological therapies, leaving time-limited use of opioid analgesics to those who did not 
achieve adequate pain relief with this first approach. While addiction is the main concern in 
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younger adults who are on opioid analgesics, in older adults the main concern is the risk of 
adverse events, that impose great harm for these patients. The best way to manage 
individuals with musculoskeletal pain who do not respond to non-opioid medications is still 
unclear. At this moment It is not possible to suggest a safer and more effective alternative to 
opioid analgesics. Non-pharmacological treatment, however, might be an interesting 
approach, particularly for patients with persistent pain.  
 
As it was shown in Chapter Three, allied health services are underused in the management of 
painful vertebral compression fracture in older adults and they could be a good alternative to 
avoiding indiscriminate use of opioids. While this thesis reinforces the importance of better 
pain treatment in older people, it shows that relying exclusively on analgesics and excluding 
non-pharmacological approaches is not ideal. Comprehensive assessment, multi-modal 
therapy and multidisciplinary approach have always been an important part of the geriatric 
care and it would not be different when dealing with musculoskeletal pain.  
 
5.3 Concluding remarks 
a) Chronic musculoskeletal pain is an independent risk factor for the development of the 
CHS frailty phenotype; 
b) Frailty does not increase the risk of developing chronic or intrusive pain. Although 
frailty may be associated with risk of intrusive pain, this association seems to be 
confounded by age, body mass index, comorbidities and depression; 
c) In the last decade, general practitioners in Australia have been treating pain related 
to vertebral compression fractures with opioid analgesics in low doses;  
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d) Allied health care services have been underused as part of a pain management 
strategy in Australian older adults with vertebral compression fractures; 
e) Opioid analgesics offer only small effects over placebo on pain and function for older 
people with musculoskeletal conditions. The risk of adverse events is considerably 
higher; 
f) In older populations, the effect of opioid analgesics in chronic musculoskeletal 
conditions is not influenced by dosage (in daily doses varying from 10 to 300 mg 
morphine equivalents) or treatment duration.  
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APPENDIX A 
Supplementary material for the Chapter Three:  Management of 
vertebral compression fracture in general practice:  
BEACH program 
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Calculating the “National annual estimated encounters”  
 
The “National annual estimated encounters” gives the estimated number of encounters in a 
year for general practice across Australia, at which vertebral compression fractures (VCF) is 
managed. It is calculated as [average annual number of encounters with at least one specified 
condition managed (n) / average annual number of recorded encounters within the specified 
study period] X average annual number of general practice consultations claimed from 
Medicare in the specified year.  
 
The table below lists the number of BEACH encounters for each year. 
 
BEACH Year 
Number of encounters 
Raw 
(weighted) 
April 2005-March 2006 
101,700 
(101,993.0) 
April 2006-March 2007 
93,000 
(91,804.7) 
April 2007-March 2008 
95,300 
(95,897.7) 
April 2008-March 2009 
101,100 
(96,687.7) 
April 2009-March 2010 
98,800 
(101,349.0) 
April 2010-March 2011 
95,800 
(95,839.0) 
April 2011-March 2012 98,400 
(99,030.0) 
April 2012-March 2013 97,800 
(98,563.9) 
April 2013-March 2014 95,900 
(95,879.0) 
April 2014-March 2015 99,500 
(98,728.4) 
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The table below lists the number of non-specialist GP Medicare services for each financial 
year (July-June). These numbers are used for each specified BEACH year (April-March).  
BEACH year Annual GP consultations^ 
2005–06 101,100,000 
2006–07 103,400,000 
2007–08 109,500,000 
2008–09 113,000,000 
2009–10 116,600,000 
2010–11 119,200,000 
2011–12 123,900,000 
2012–13 128,700,000 
2013–14 134,200,000 
2014-15 139,400,000 
 
^Annual GP consultations are rounded to the nearest 100,000. 
Available online at: <http://health.gov.au/internet/main/publishing.nsf/Content/Quarterly-
Medicare-Statistics>  
Therefore, the “National annual estimated encounters” were calculated as follows: 
(21.1 / 97,300) x 118,900,000 = 25,670, rounded to 26,000 (22,000-29,000) 
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APPENDIX B 
Supplementary material for the Chapter Four:  Efficacy and safety 
of oral and transdermal opioid analgesics for musculoskeletal pain 
in older adults: a systematic review of randomized, placebo-
controlled trials 
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Search strategy:  
Ovid MEDLINE, Ovid EMBASE and Ovid AMED 
Search terms for design  
randomized controlled trial.pt. or controlled clinical trial.pt. or comparative study.pt. or 
clinical trial.pt. or randomized.ab. or placebo.ab,ti. or randomly.ab,ti.  
(animals not (humans and animals)).sh. 
1 not 2  
Search terms for musculoskeletal pain 
exp osteoarthritis/ or osteoarthriti$.ti,ab. or osteoarthro$.ti,ab. or gonarthriti$.ti,ab. or 
gonarthro$.ti,ab. or coxarthriti$.ti,ab. or coxarthro$.ti,ab. or arthros$.ti,ab. or arthrot$.ti,ab. 
or  
((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or discomfort$)).ti,ab. or ((knee$ or hip$ or 
joint$) adj3 stiff$).ti,ab. or Arthritis, Psoriatic/ or Arthritis, Rheumatoid/ or Arthritis/ or 
Arthritis, Gouty/ or arthritis.ti,ab. or gout.ti,ab or dorsalgia.ti,ab. or exp Back Pain/ or 
backache.ti,ab. or exp Low Back Pain/ or (lumbar adj pain).ti,ab. or coccyx.ti,ab. or 
coccydynia.ti,ab. or sciatica.ti,ab. or sciatic neuropathy/ or spondylosis.ti,ab. or 
lumbago.ti,ab. or back disorder$.ti,ab. or neck muscles.sh. or exp Neck/ or exp neck pain/ or 
whiplash injuries.sh. or neck.ti,ab. or exp Spine/ or discitis.ti,ab. or exp Spinal Diseases/ or  
(disc adj degeneration).ti,ab. or (disc adj prolapse).ti,ab. or (disc adj herniation).ti,ab. or 
spinal fusion.sh. or  (facet adj joints).ti,ab. or intervertebral disc.sh. or Intervertebral Disc or 
Displacement.sh. or spinal stenosis or canal stenosis or (spin* adj3 stenosis) or (lumbar adj3 
stenosis) or (lateral adj3 stenosis) or (central adj3 stenosis) or (foramin* adj3 stenosis or 
neurogenic claudication or radiculopathy or radicular pain or lumbar radicular pain or 
spondylolisthesis or (lumb* adj5 spondyl*) or spondylosis).mp. or spinal fractures/  or 
(Vertebr$ adj3 fracture$).ti,ab or vertebral compression fracture$.ti,ab or (Osteopor$ adj3 
fracture$).ti,ab or (osteopor$ adj3 compress$).ti,ab or (verteb$ adj3 fracture$).ti,ab or 
(spin$ adj3 fracture$).ti,ab or (lumbar adj3 fracture$).ti,ab or (thoracic adj3 fracture$).ti,ab 
or (compress$ adj3 fracture$).ti,ab or Shoulder Pain/ or Shoulder Impingement Syndrome/ 
or Rotator Cuff/ or exp Bursitis/ or ((should$ or rotator cuff ) adj5 (bursitis or adhesive 
capsulitis or arthriti$ or frozen or impinge$ or tend?nitis or pain$)).ti,ab or rotator cuff.mp 
or adhesive capsulitis.mp or Musculoskeletal Pain/ or Chronic Pain/ or fibromyalgia.mp. or 
Fibromyalgia/ or (skelet* adj3 pain).mp. or (muscul* adj3 pain).mp. or (chronic adj3 
pain).mp  or Myofascial Pain Syndromes/ or myofascial pain.ti,ab. 
Search terms for opioids  
exp Analgesics, Opioid/ or exp Narcotics/ or acetyldihydrocodeine.tw. or alfentanil.tw. or 
allylprodine.tw. or alphamethylfentanyl.tw. or alphaprodine.tw. or benzylmorphine.tw. or 
betaprodine.tw. or buprenorphine.tw. or butorphanol. tw. or bremazocine.tw. or 
codeine.tw. or  
contin.tw. or dextromoramide.tw. or dextropropoxyphene.tw. or dezocine.tw. or 
diacetylmorphine.tw. or diamorphine.tw. or dihydrocodeine.tw. or dihydromorphine.tw. or 
dihydromorphone.tw. or diphenoxylate.tw. or dipipanone.tw. or enadoline.tw. or 
ethylketazocine.tw. or ethylmorphine.tw. or etonitazene.tw. or etorphine.tw. or 
fentanyl.tw. or heroin.tw. or hydrocodone.tw. or hydromorphin$.tw. or hydromorphone.tw. 
or ketazocine.tw. or ketobemidone.tw. or lefetamine.tw. or levomethadon.tw. or 
levomethadyl.tw. or levomethorphan$.tw. or levorphanol. tw. or loperamide.tw. or 
meperidine.tw. or meptazinol.tw. or methadone.tw. or methadyl.tw. or 
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methylmorphine.tw. or morphin$.tw. or nalbuphine.tw. or narcotic$.tw or nicocodeine.tw. 
or nicomorphine.tw. or normorphine.tw. or noscapin$.tw. or ohmefentanyl.tw. or 
opiate$.tw. or opioid$.tw. or opium.tw. or oripavine.tw. or oxycodone.tw. or oxycontin.tw. 
or oxymorphone.tw. or papaveretum.tw. or papaverin.tw. or pentazocine.tw. or 
percocet.tw. or peronine.tw. or pethidine.tw. or phenazocine.tw. or phencyclidine.tw. or 
pholcodine.tw. or piritramid$.tw. or prodine.tw. or promedol.tw. or propoxyphene.tw. or 
remifentanil.tw. or sufentanil.tw. or tapentadol.tw. or thebaine.tw. or tilidine.tw. 
Cochrane Library via Wiley  
Search terms for musculoskeletal pain  
MeSH descriptor Arthritis explode all trees OR arthritis OR MeSH descriptor Osteoarthritis 
explode all trees OR osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro* OR 
coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR (knee* OR hip* OR joint*) near/3 
(pain* OR ach* OR discomfort*) OR (knee* OR hip* OR joint*) near/3 (stiff*) or MeSH 
descriptor Gout explode all trees or gout or MeSH descriptor Back Pain explode all trees OR 
dorsalgia OR backache OR MeSH descriptor Low Back Pain explode all trees OR (lumbar next 
pain) or coccyx or coccydynia or sciatica or spondylosis OR MeSH descriptor Spine explode 
all trees OR MeSH descriptor Spinal Diseases explode all trees OR lumbago or discitis or (disc 
near degeneration) or (disc near prolapse) or (disc near herniation) OR facet joints OR MeSH 
descriptor Intervertebral Disk explode all trees OR MeSH descriptor Cauda Equina explode 
all trees OR lumbar near vertebra* OR spinal near stenosis OR slipped near (disc* or disk*) 
OR degenerat* near (disc* or disk*) OR stenosis near (spine or root or spinal) OR displace* 
near (disc* or disk*) OR prolap* near (disc* or disk*) OR MeSH descriptor Sciatic 
Neuropathy explode all trees OR sciatic* OR back disorder* OR back near pain OR MeSH 
descriptor Neck, this term only OR MeSH descriptor Neck Pain explode all trees OR MeSH 
descriptor Neck Muscles explode all trees OR MeSH descriptor Neck Injuries explode all 
trees OR MeSH descriptor Whiplash Injuries explode all trees OR whiplash OR neck pain OR 
neck disorder* OR cervical near vertebra* OR neck near pain or spinal stenosis or canal 
stenosis or (spin* adj3 stenosis) or (lumbar adj3 stenosis) or (lateral adj3 stenosis) or 
(central adj3 stenosis) or (foramin* adj3 stenosis) or neurogenic claudication or 
radiculopathy or radicular pain or lumbar radicular pain or spondylolisthesis or (lumb* adj5 
spondyl*) or spondylosis or MeSH descriptor Fractures, Compression explode all trees OR 
MeSH descriptor Spinal Cord Compression explode all trees OR MeSH descriptor Spinal 
Fractures explode all trees OR vertebral near compression or fracture OR thoracic or lumbar 
or spin* near fracture* OR compression near fracture OR (thoracic or lumbar or spin*) near 
compression OR “fractured vertebrae” or MeSH descriptor Shoulder pain explode all trees 
or MeSH descriptor Shoulder Impingement Syndrome explode all trees or MeSH descriptor 
Rotator Cuff explodes all trees or MeSH descriptor Bursitis explode all trees or ((should$ or 
rotator cuff) adj5 (bursitis or adhesive capsulitis or arthriti$ or frozen or impinge$ or 
tend?nitis or pain$)) or rotator cuff or adhesive capsulitis or MeSH descriptor Fibromyalgia 
explode all trees OR MeSH descriptor Myofascial Pain Syndromes explode all trees OR MeSH 
descriptor Chronic pain explode all trees OR MeSH descriptor Musculoskeletal pain explode 
all trees OR MeSH descriptor Artralgia explode all trees in Clinical Trials 
Search terms for Opioids  
MeSH descriptor Analgesics, Opioid explode all trees OR MeSH descriptor Narcotics explode 
all trees OR (acetyldihydrocodeine OR alfentanil OR allylprodine OR alphamethylfentanylOR 
alphaprodine OR benzylmorphine OR betaprodine OR bezitriamide OR buprenorphine OR 
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butorphanol OR bremazocine OR carfentan* OR codeine OR contin OR dextromoramide OR 
dextropropoxyphene OR dezocine OR diacetylmorphine OR diamorphine OR dihydrocodeine 
OR dihydromorphine OR dihydromorphone OR diphenoxylate OR dipipanone OR enadoline 
OR ethylketazocine OR ethylmorphine OR etonitazene OR etorphine OR fentanyl OR 
heroinOR hydrocodone OR hydromorphin* OR hydromorphone OR ketazocine OR 
ketobemidone OR lefetamine OR levomethadon OR levomethadyl OR levomethorphan* OR 
levorphanol OR loperamide OR meperidine OR meptazinol OR methadone OR methadyl OR 
methylmorphineOR morphin* OR nalbuphine OR narcotic* OR nicocodeine OR 
nicomorphine OR normorphine OR noscapin* OR ohmefentanyl OR opiate* OR opioid* OR 
opium OR oripavine OR oxycodone OR oxycontin OR oxymorphone OR papaveretum OR 
papaverin OR pentazocine OR percocet OR peronine OR pethidine OR phenazocine OR 
phencyclidine OR pholcodine OR piritramid* OR prodine OR promedol OR propoxyphene OR 
remifentanil OR sufentanil OR tapentadol OR thebaine OR tilidine) in Clinical Trials 
CINAHL via EBSCO 
Search terms for design 
MH “Clinical Trials+” or MH “Random Assignment” or MH “Double-Blind Studies” or MH 
“Single-Blind Studies” or TX (clin$ n25 trial$) or TX (sing$ n25 blind$) or TX (sing$ n25 
mask$) or TX (doubl$ n25 blind$) or TX (doubl$ n25 mask$) or TX (trebl$ n25 blind$) or TX 
(trebl$ n25 mask$) or TX (tripl$ n25 blind$) or TX (tripl$ n25 mask$) or MH “Placebos” or TX 
placebo$ or TX random$ or MH “Study Design+” or MH “Comparative Studies” or  MH 
“Evaluation Research” or MH “Prospective Studies+” or TX (control$ or prospectiv$ or 
volunteer$)  
Search terms for musculoskeletal pain 
MH "Arthritis+" OR TX arthritis OR MH "Arthritis, Rheumatoid+" OR MH "Gout" OR TX gout 
OR MH "Arthritis, Psoriatic" OR MH "Spondylarthritis+" or TX osteoarthriti$ or MH 
“Osteoarthritis” or TX arthritis or TX osteoarthro$ or TX gonarthriti$ or TX gonarthro$ or TX 
coxarthriti$ or TX coxarthro$ or TX arthros$ or TX arthrot$ or TX (knee$ n3 pain$) or TX 
(hip$ n3 pain$) or TX (joint$ n3 pain$) or TX (knee$ n3 ach$) or TX (hip$ n3 ach$) or TX 
(joint$ n3 ach$) or TX (knee$ n3 discomfort$) or TX (hip$ n3 discomfort$) or TX (joint$ n3 
discomfort$) or TX (knee$ n3 stiff$) or TX (hip$ n3 stiff$) or TX (joint$ n3 stiff$) or TX 
lumbago or MH “Spondylolisthesis” or MH “Spondylosis” or MH “Thoracic vertebrae” or TX 
(lumbar n2 vertebrae) or MH “Lumbar vertebrae” or TX coccydynia or TX (back disorder*) or 
TX coccyx or TX sciatica or MH “Sciatica” or MH “Coccyx” or TX (lumbar n5 pain) or TX 
(lumbar w1 pain) or TX backache or (MH “low back pain” or MH “Back pain”) or (MH “Back 
pain+”) or TX dorsalgia or MH "Whiplash Injuries" or MH "Cervical Vertebrae" or MH "Neck 
Pain" or MH "Neck" or "neck muscles" or MH "Neck Muscles" or TX (disc w5 herniation) or 
TX (disc W5 prolapse) or TX(disc W5 degeneration) or MH "Spinal Diseases+" or MH 
"Intervertebral Disk" or (MH "Spine+") or MH "Spinal Stenosis" or TX (spinal stenosis") or 
TX(spin* stenosis) or TX(canal stenosis) or TX(lumbar stenosis) or TX(lateral stenosis) or 
TX(central stenosis) or TX(foramin* stenosis) or MH "Intermittent Claudication" or TX 
(neurogenic claudication) or MH "Radiculopathy" or TX radiculopathy or TX (radicular pain) 
or TX (lumbar radicular pain) or MH “FRACTURES, VERTEBRAL COMPRESSION” or MH 
“FRACTURES, COMPRESSION” or MH “SPINAL FRACTURES” or MH “OSTEOPOROSIS/ 
[COMPLICATIONS] OR OSTEOPOROSIS, POSTMENOPAUSAL [COMPLICATIONS]” OR TX 
lumbar vertebrae” or TX (verteb* compression) or TX (verteb* fracture*) or TX (osteopor* 
fracture*) or TX(osteopor* vertebra*) or TX(compress* adj3 fracture*) or TX (spinal 
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compress*) or TX(vertebra* adj3 compression adj3 fracture*) or TX(spinal fracture*) or MH 
“Shoulder Pain” or MH “Shoulder Impingement Syndrome” or MH “Rotator Cuff” or MH 
“Bursitis” or TX((should$ or rotator cuff ) adj5 (bursitis or adhesive capsulitis or arthriti$ or 
frozen or impinge$ or tend?nitis or pain$)) or TX (rotator cuff) or TX(adhesive capsulitis) or 
MH “Musculoskeletal Pain” or MH “Chronic Pain” or TX fibromyalgia or MH “Fibromyalgia” 
or TX (skelet* adj3 pain) or TX (muscul* adj3 pain) or TX (chronic adj3 pain) or MH 
"Myofascial Pain Syndromes+" OR (myofascial pain)   
Search terms for Opioids 
MH “Analgesics, Opioid” or MH “Narcotics” or TX acetyldihydrocodeine or TX alfentanil or 
TX allylprodine or TX alphamethylfentanyl or TX alphaprodine or TX benzylmorphine or TX 
betaprodine or TX bezitriamide or TX buprenorphine or TX butorphanol or TX bremazocine 
or TX carfentan$ or TX codeine or TX contin or TX dextromoramide or TX 
dextropropoxyphene or TX dezocine or TX diacetylmorphine or TX diamorphine or TX 
dihydrocodeine or TX dihydromorphine or TX dihydromorphone or TX diphenoxylate or TX 
dipipanone or TX enadoline or TX ethylketazocine or TX ethylmorphine or TX etonitazene or 
TX etorphine or TX fentanyl or TX heroin or TX hydrocodone or TX hydromorphin$ or TX 
hydromorphone or TX ketazocine or TX ketobemidone or TX lefetamine or TX levomethadon 
or TX levomethadyl or TX levomethorphan$ or  TX levorphanol or TX loperamide or TX 
meperidine or TX meptazinol or TX methadone or TX methadyl or TX methylmorphine or TX 
morphin$ or TX nalbuphine or TX narcotic$ or TX nicocodeine or TX nicomorphine or TX 
normorphine or TX noscapin$ or TX ohmefentanyl or TX opiate$ or TX opioid$ or TX opium 
or TX oripavine or TX oxycodone or TX oxycontin or TX oxymorphone or TX papaveretum or 
TX papaverin or TX pentazocine or TX Percocet or TX peronine or TX pethidine or TX 
phenazocine or TX phencyclidine or TX pholcodine or TX piritramid$ or TX prodine or TX 
promedol or TX propoxyphene or TX remifentanil or TX sufentanil or TX tapentadol or TX 
thebaine or TX tilidine  
Web of Science 
Search terms for design  
randomized controlled trial or controlled clinical trial or comparative study or clinical trial or 
randomized or placebo or randomly  
Search terms for musculoskeletal pain 
osteoarthritis or osteoarthro$ or gonarthriti$ or gonarthro$ or coxarthriti$ or coxarthro$ or 
arthros$ or arthrot$ or psoriatic arthritis or rheumatoid arthritis or arthritis or gouty 
arthritis or gout or dorsalgiaor back Pain or backache or coccydynia.ti,ab. or sciatica or 
spondylosis or lumbago or neck muscles or neck pain or whiplash injuries or spine or discitis 
or disc degeneration or facet joints or intervertebral disc or spinal stenosis or canal stenosis 
or neurogenic claudication or radiculopathy or radicular pain or lumbar radicular pain or 
spondylolisthesis or spinal fractures or vertebral compression fracture$ or osteoporotic 
fracture or vertebral fracture or spinal fracture or shoulder pain or shoulder Impingement or 
rotator cuff or bursitis or adhesive capsulitis or frozen or tend$nitis or musculoskeletal pain 
or chronic pain or fibromyalgia or myofascial pain  
Search terms for Opioids  
opioid or narcotics or acetyldihydrocodeine or alfentanil or allylprodine or 
alphamethylfentanyl or alphaprodine or benzylmorphine or betaprodine or buprenorphine 
or butorphanol or bremazocine or codeine or contin or dextromoramide or 
dextropropoxyphene or dezocine or diacetylmorphine or diamorphine or dihydrocodeine or 
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dihydromorphine or dihydromorphone or diphenoxylate or dipipanone or enadoline or 
ethylketazocine or ethylmorphine or etonitazene or etorphine or fentanyl or heroin or 
hydrocodone or hydromorphin$ or hydromorphone or ketazocine or ketobemidone or 
lefetamine or levomethadon or levomethadyl or levomethorphan$ or levorphanol or 
loperamide or meperidine or meptazinol or methadone or methadyl or methylmorphine or 
morphin$ or nalbuphine or narcotic$ or nicocodeine or nicomorphine or normorphine or 
noscapin$ or ohmefentanyl or opiate$ or opioid$ or opium or oripavine or oxycodone or 
oxycontin or oxymorphone or papaveretum or papaverin or pentazocine or percocet or 
peronine or pethidine or phenazocine or phencyclidine or pholcodine or piritramid$ or 
prodine or promedol or propoxyphene or remifentanil or sufentanil or tapentadol or 
thebaine or tilidine 
LILACS via BVS 
(PT randomized controlled trial OR PT controlled clinical trial OR PT multicenter study OR 
MH randomized controlled trials as topic OR MH controlled clinical trials as topic OR MH 
multicenter studies as topic OR MH random allocation OR MH double-blind method OR MH 
single-blind method) OR (trial$ AND placebo OR control$ OR random$) AND NOT (MH 
animals OR MH rabbits OR MH rats OR MH primates OR MH dogs OR MH cats OR MH swine 
OR PT in vitro) AND (osteoarthritis or osteoarthro$ or gonarthriti$ or gonarthro$ or 
coxarthriti$ or coxarthro$ or arthros$ or arthrot$ or psoriatic arthritis or rheumatoid 
arthritis or arthritis or gouty arthritis or gout or dorsalgiaor back Pain or backache or 
coccydynia.ti,ab. or sciatica or spondylosis or lumbago or neck muscles or neck pain or 
whiplash injuries or spine or discitis or disc degeneration or facet joints or intervertebral 
disc or spinal stenosis or canal stenosis or neurogenic claudication or radiculopathy or 
radicular pain or lumbar radicular pain or spondylolisthesis or spinal fractures or vertebral 
compression fracture$ or osteoporotic fracture or vertebral fracture or spinal fracture or 
shoulder pain or shoulder Impingement or rotator cuff or bursitis or adhesive capsulitis or 
frozen or tend$nitis or musculoskeletal pain or chronic pain or fibromyalgia or myofascial 
pain ) AND (opioid or narcotics or acetyldihydrocodeine or alfentanil or allylprodine or 
alphamethylfentanyl or alphaprodine or benzylmorphine or betaprodine or buprenorphine 
or butorphanol or bremazocine or codeine or contin or dextromoramide or 
dextropropoxyphene or dezocine or diacetylmorphine or diamorphine or dihydrocodeine or 
dihydromorphine or dihydromorphone or diphenoxylate or dipipanone or enadoline or 
ethylketazocine or ethylmorphine or etonitazene or etorphine or fentanyl or heroin or 
hydrocodone or hydromorphin$ or hydromorphone or ketazocine or ketobemidone or 
lefetamine or levomethadon or levomethadyl or levomethorphan$ or levorphanol or 
loperamide or meperidine or meptazinol or methadone or methadyl or methylmorphine or 
morphin$ or nalbuphine or narcotic$ or nicocodeine or nicomorphine or normorphine or 
noscapin$ or ohmefentanyl or opiate$ or opioid$ or opium or oripavine or oxycodone or 
oxycontin or oxymorphone or papaveretum or papaverin or pentazocine or percocet or 
peronine or pethidine or phenazocine or phencyclidine or pholcodine or piritramid$ or 
prodine or promedol or propoxyphene or remifentanil or sufentanil or tapentadol or 
thebaine or tilidine) 
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Figure S1. Study level risk of bias summary table 
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Figure S2. Risk of bias graph 
 
 
 
  
145 
 
 
 
Figure S3. Effect of opioid on pain intensity in the immediate-term follow-up 
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Figure S4. Effect of opioid on function in the immediate-term follow-up 
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Figure S5. Effect of opioid on quality of life (SF-36 physical and mental component summary) 
in the immediate-term follow-up 
 
 
 
148 
 
 
 
Figure S6. Risk of discontinuation due to adverse events – opioid vs. placebo 
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Figure S7. Risk of discontinuation due to lack of efficacy – opioid vs. placebo 
 
 
 
 
 
